[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hodgkin-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hodgkin-lymphoma":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,75,0,25,[9,44,80,106,132,161,186,209,255,287,311,348,380,420,439,477,506,543,563,593,614,683,705,726,747],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632525","integration-of-adaptive-proton-therapy-in-pediatric-solid-tumors-and-hodgkins-lymphoma-100632525",false,"NCT07514819","Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma","Inclusion Criteria:\n\n* Participants diagnosed with solid tumors, including Rhabdomyosarcoma, Osteosarcoma, Ewing sarcoma, other sarcomas and carcinomas or also Hodgkin's lymphoma.\n* Participants who receive proton radiation therapy at St. Jude Children's Research Hospital.\n* Research participant or legal guardian\u002Frepresentative gives written informed consent.\n\nExclusion Criteria:\n\n* Participants who are not diagnosed with solid tumors or Hodgkin's lymphoma.\n* Participants who are diagnosed with Wilm's tumor or neuroblastoma\n* Participants who do not undergo proton therapy.\n* Participants who are prescribed equal or less than 5 fractions of proton therapy.\n* Participants with severe comorbid conditions that may impact imaging feasibility.\n* Inability to obtain written consent from research participant or legal guardian\u002Frepresentative.\n* Females of child-bearing potential cannot be pregnant or breast-feeding. Female participants \\>10 years of age or post-menarchal must have a negative serum or urine pregnancy test\n\nAll participants receiving proton therapy at St. Jude Children's Research Hospital will be screened for participation on this research protocol based on the Inclusion Criteria and the Exclusion Criteria. Qualified candidates will be selected during the consultation.","ALL",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"NA","Pediatric patients receiving proton therapy for solid tumors or Hodgkin's lymphoma may experience anatomical changes during treatment that can affect proton therapy accuracy. This prospective single-arm study uses regular low-dose imaging to monitor these changes and adjust treatment plans as needed. Participants will receive weekly or every-other-week CT scans, with MRI when appropriate, to assess whether the original plan remains accurate. Treatment plans will be updated if tumor coverage decreases by more than 5% or if radiation dose to normal tissues increases by more than 10%; otherwise, the original plan will continue. The study aims to determine how often plan adjustments are needed and to identify which disease sites are most likely to experience significant anatomical changes during treatment.\n\nPrimary Objective:\n\n* Define the frequency of replanning necessary to ensure tumor coverage never falls below 95% (or 5% drop) of the prescribed daily dose in participants with intact (gross) tumors to keep the tumor control optimal throughout the multi-week treatment regimen.\n* Define the frequency of replanning necessary to ensure organs-at-risk (critical organs) do not deviate by more than 10% of the initially approved dose constraints to keep the normal tissue complication minimal throughout the multi-week treatment regimen.\n\nSecondary Objectives\n\n* Establish a cone beam CT (CBCT)-based framework for quantifying body surface changes throughout the treatment course. This goal will be achieved by developing a novel algorithm that detects and tracks external anatomical variations longitudinally, without requiring CBCT image enhancement, enabling precise assessment of daily participant setup consistency and anatomical stability.\n* Overcome daily CBCT quality limitations by generating synthetic CT images that accurately represent daily anatomy and support proton dose recalculation or verification planning. This goal will be achieved by developing a hybrid pipeline that integrates deep learning models with the deformable image registration algorithm, trained and validated on disease site-specific data. This will enable precise dose mapping and tissue density estimation, directly supporting adaptive planning decisions without the need of diagnostic- quality CT images.",[25,26,27,28,29,30,31],"Pediatric Solid Tumors","Rhabdomyosarcoma","Ewing Sarcoma","Osteosarcoma","Hodgkin Lymphoma","Bone Tumor","Soft Tissue Sarcoma","RECRUITING","2026-08-20",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":33,"type":36},{"date":39,"type":19},"2031-08",{"name":41,"class":42},"St. Jude Children's Research Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100514375","phase-2-efficacy-and-safety-of-frontline-tislelizumab-in-patients-with-de-novo-hodgkin-lymphoma-unsuitable-for-standard-frontline-chemotherapy-100514375","NCT05977673","Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy","Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy: a Phase II, Open-label Study","FIL_Tisle-HL","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of de novo classical Hodgkin Lymphoma (cHL). Note: Availability of either block or unstained slides plus stained slides used by the local pathologist to make diagnosis, and of all pathology reports is mandatory for the study to perform central pathology review for confirmation of cHL diagnosis and for biological biomarkers assessments. Central pathology confirmation is not required to start treatment;\n* Patients \\>= 65 years ineligible for frontline standard chemotherapy (mainly due to medical comorbidities);\n* Treatment naïve;\n* Measurable disease defined as presence of both fluorodeoxyglucose-avid nodal involvement and at least one nodal target lesion measurable in two diameters (and at least 1.5 cm in its major diameter); • Indication for systemic treatment, i.e., all stages except IA without a large tumor burden, as radiotherapy is regarded curative in those patients;\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) \\\u003C= 2;\n* Adequate organ and marrow function as defined below:\n\n  * Absolute neutrophil count (ANC) \\> 109\u002FL (without growth factor support within 7 days of ANC measurement), unless due to bone marrow involvement by lymphoma\n  * Platelet \\> 50 x 109\u002FL (without growth factor support or transfusion within 7 days of platelets measurement) , unless due to bone marrow involvement by lymphoma\n  * Hemoglobin \\> 8 g\u002FdL (prior transfusion is acceptable)\n  * Creatinine clearance ≥ 30 ml\u002Fmin (as estimated by the Cockcroft-Gault equation or as measured by nuclear medicine scan or 24-hour urine collection)\n  * Aspartate aminotransferase (AST)\u002Fserum glutamic oxaloacetic transaminase, and alanine aminotransferase (ALT)\u002Fserum glutamic pyruvic transaminase ≤ 3.0 × upper limit of normal (ULN)\n  * Serum total bilirubin \\\u003C 1.5 × ULN (or \\\u003C 3 x ULN in case of documented Gilbert's syndrome)\n* Life expectancy ≥ 6 months;\n* Men must agree to use effective contraception if sexually active. This applies for the time period between signing of the informed consent form and 4 months after last tislelizumab dose. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control method, e.g. vasectomy, use of condoms or complete sexual abstinence, when this is in line with the preferred and usual lifestyle of the subject.The use of condoms by male patients is required unless the female partner is permanently sterile. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods for the female partner) and withdrawal are not acceptable methods of contraception.\n* Subject voluntarily signs and dates an informed consent form approved by an National Ethics Committee (NEC) prior to the initiation of any screening or study-specific procedures, indicating that they understand the purpose of and procedures required for the study and are willing to participate in it;\n* Subject must be able to adhere to the study visit schedule and other protocol requirements, and to return to enrolling institution for follow-up (during the active monitoring phase of the study).\n\nExclusion Criteria:\n\n* Nodular lymphocyte predominant HL;\n* Any previous treatment (including radiation therapy) for HL;\n* Any active autoimmune disease requiring systemic treatment (including disease-modifying agents, corticosteroids, immunosuppressants) in the past 2 years; Note: Patients with the following diseases are not excluded and may proceed to further screening: Type I diabetes under control; Hypothyroidism (provided it is managed with hormone replacement therapy only); Controlled celiac disease;\n* Has known history of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis, acute lung diseases or evidence of dyspnea at rest or pulse oximetry of \\\u003C 92% while breathing room air;\n* A history of previous exposure to anti-PD1, anti-PDL1 or anti-PDL2 or anti-CTLA-4 agents for any disease other than HL;\n* Use of systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications ≤14 days from registration; Note: Inhaled or topical steroids and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease;\n* Known infection with HIV, human T-cell lymphotropic virus-1, -2; • Serologic status reflecting active hepatitis B defined as presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) (mandatory testing). Patients with occult or prior HBV infection (respectively defined as patient with HBsAg-\u002FHBcAb+ and patients HBsAg+ with HBV DNA undetectable) are eligible, provided that they are willing to undergo prophylactic antiviral medication according to local standard of care. Patients who have protective titers of hepatitis B surface antibody (HBsAb) after vaccination are eligible;\n* Presence of hepatitis C virus (HCV) antibody (mandatory HCV antibody serology testing). Patients with presence of HCV antibody are eligible only if PCR is negative for HCV RNA;\n* Hypersensitivity to tislelizumab or any of its excipients;\n* Active central nervous system (CNS) involvement or leptomeningeal metastases involvement;\n* Evidence of other clinically significant uncontrolled and\u002For active systemic infection (viral, bacterial or fungal), including active ongoing infection from SARS-CoV-2;\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens;\n* Major surgery within 4 weeks of the first dose of study drug;\n* Vaccination with a live vaccine within 4 weeks prior to the first dose of study drug;\n* Clinically significant cardiovascular disease including the following:\n\n  * Myocardial infarction within 6 months before screening;\n  * Unstable angina within 3 months before screening;\n  * New York Heart Association Classification III or IV congestive heart failure;\n  * History of clinically significant arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes);\n  * QTcF \\> 480 msecs based on Fridericia's formula;\n  * History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place;\n  * Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure \\> 170 mm Hg and diastolic blood pressure \\> 105 mm Hg at screening;\n* Significant history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent;\n* Any history of other active malignancies within 3 years prior to study entry, with the exception of adequately treated in situ carcinoma of the cervix uterine, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin, previous malignancy confined and surgically resected with curative intent;\n* History of severe hypersensitivity reactions to other monoclonal antibodies;\n* Concurrent participation in another therapeutic clinical trial.","65 Years",{"count":54,"type":19},28,[56],"PHASE2","This is a multicenter, prospective, non-randomized, open-label, phase 2 clinical study to evaluate the efficacy and safety of tislelizumab in patients with de novo Hodgkin Lymphoma deemed ineligible to frontline chemotherapy.",[29],[60,61,62,63,64,65,66,67,68,69],"Lymphoma","Hodgkin","Tislelizumab","PD1","Checkpoint","Inhibitor","De novo","Unsuitable","Chemotherapy","Immune","2026-08-17",{"date":72,"type":36},"2026-08-19",{"date":74,"type":36},"2024-05-23",{"date":76,"type":19},"2030-11",{"name":78,"class":42},"Fondazione Italiana Linfomi - ETS",12,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":20,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":43},"100627624","cd45be-hspc--cart-45-cells-100627624","NCT07451054","CD45BE-HSPC + CART-45 Cells","Phase 1 Study of Autologous Anti-CD45 CAR T Cells in Combination With CD45 Base Edited HSPCs in Patients With Relapsed or Refractory Hematologic Malignancies","Inclusion Criteria:\n\n1\\. Signed informed consent form 2. Male or females age ≥ 18 years 3. Disease-Specific Criteria\n\na. B-cell Non-Hodgkin Lymphoma (B-cell NHL)- including the following sub-types:\n\ni. Patients with any of the following large B-cell lymphoma diagnoses who meet the prior treatment criteria outlined below: Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL NOS); Primary Cutaneous DLBCL; Primary Mediastinal (thymic) Large B-cell Lymphoma; ALK+ Anaplastic Large B-cell Lymphoma; High-Grade B-cell Lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements (i.e., \"Double or Triple Hit\"); High-grade B-cell Lymphoma, NOS; T-cell Rich B-cell Lymphoma; Transformed Follicular Lymphoma; or any aggressive B-cell lymphoma arising from indolent lymphoma.\n\n1\\. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND 2. Relapsed\u002Frefractory disease after at least 2 prior lines of appropriate therapy.\n\nii. Follicular Lymphoma\n\n1. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND\n2. Relapsed\u002Frefractory disease after at least 2 prior lines of systemic therapy (not including a single agent monoclonal antibody therapy).\n\niii. Mantle Cell Lymphoma\n\n1. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND\n2. Relapsed\u002Frefractory disease after at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.\n\n   iv. Marginal Zone Lymphoma- relapsed\u002Frefractory disease after at least 2 prior lines of appropriate therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Note: Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.\n\n   b. T-cell Non-Hodgkin Lymphoma (T-cell NHL)\n\n   i. Histologically or cytologically confirmed relapsed or refractory (r\u002Fr) mature aggressive T- and NK-cell neoplasms as defined in the 5th edition of the WHO Classification of Hematolymphoid tumors, which includes any of the following diagnoses:\n\n   • Peripheral T-cell Lymphoma, NOS (PTCL-NOS);\n\n   • Nodal T-cell Lymphomas with T Follicular Helper \\[TFH\\] Phenotype, including Follicular T cell Lymphoma, Angioimmunoblastic Lymphoma, or Anaplastic Large Cell Lymphoma (ALCL);\n\n   • ALK+ or ALK-, Enteropathy-Associated T-cell Lymphoma (EATL);\n\n   • Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL);\n\n   • Extranodal NK\u002FT-cell Lymphoma;\n\n   • Primary Cutaneous T-cell Lymphoma (CTCL);\n\n   • Transformed Mycosis Fungoides (tMF) without blood involvement;\n\n   • Primary Cutaneous Aggressive Epidermotropic CD8+ Cytotoxic T-Cell Lymphoma;\n\n   • Subcutaneous Panniculitis-like T-cell Lymphoma.\n\n   ii. Must have received at least one prior line of systemic therapy for their lymphoma. Additional prior treatment provisions required for the following indications:\n\n1\\. Participants with Anaplastic Large Cell Lymphoma (ALCL) must have received prior Brentuximab vedotin, unless contraindicated.\n\n2\\. Participants with Subcutaneous Panniculitis-like T-cell Lymphoma or Transformed Mycosis Fungoides (tMF) must have received at least 2 prior lines of systemic therapy.\n\nc. Hodgkin Lymphoma (HL)\n\ni. Patients with histologically proven classical Hodgkin Lymphoma that is CD45 positive by IHC or flow cytometry by a CLIA certified laboratory; AND\n\nii. Relapsed\u002Frefractory disease after at least 2 prior lines of therapy which must include the following:\n\n1. Brentuximab vedotin and immune checkpoint inhibitors (unless contraindicated); AND\n2. Autologous stem cell transplant (unless patient has chemorefractory disease to salvage treatment) d. Large Cell Transformation of CLL (Richter's Transformation) i. Patients must be primary refractory or received at least 1 prior line of treatment for Richter's Transformation.\n\n4\\. Patients are appropriate candidates for autologous HSCT as per physician-investigator clinical discretion\n\n5\\. Patients with relapsed disease after prior allogeneic SCT must meet the following criteria:\n\na. Have no active GVHD and require no immunosuppression\n\nb. Are more than 6 months from transplant at the time of physician-investigator confirmation of eligibility\n\n6\\. Adequate organ function defined as:\n\n1. Serum creatinine ≤ 1.5x ULN or estimated creatinine clearance ≥ 35 mL\u002Fmin and not on dialysis\n2. ALT\u002FAST ≤ 3 x ULN\n3. Direct bilirubin ≤ 2.0 mg\u002Fdl; for patients with Gilbert's syndrome direct bilirubin must be ≤ 3.0 mg\u002Fdl\n4. Left Ventricular Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO\u002FMUGA\n5. DLCO \\> 45% predicted value; adjusted for level of hemoglobin\n6. Must have minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen \\> 92% on room air 7. ECOG Performance Status 0-1\n\nExclusion Criteria:\n\n1. Active hepatitis B or hepatitis C infection\n2. Any active, uncontrolled infection.\n3. Class III\u002FIV cardiovascular disability according to the New York Heart Association Classification.\n4. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.\n5. Severe, active co-morbidity that, in the opinion of the physician-investigator, would preclude participation in this study.\n6. Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n7. Active acute or chronic GVHD requiring systemic therapy.\n8. Dependence on systemic steroids or immunosuppressant medications. For additional details regarding use of steroid and immunosuppressant medications.\n9. Active CNS involvement. Patients with a history of CNS involvement that was successfully treated are eligible. A CNS evaluation is only required for eligibility if a subject is experiencing signs\u002Fsymptoms of CNS involvement.\n10. Patients with evidence of a circulating T-cell malignancy as measured by flow cytometry.\n11. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).\n12. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.\n13. Pregnant or nursing (lactating) patients. Participants of reproductive potential must agree to use acceptable birth control methods.","18 Years",{"count":89,"type":19},42,[91],"PHASE1","This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as \"CART-45 cells\") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as \"CD45BE-HSPC\") in patients with relapsed or refractory hematologic malignancies.",[94,95,96,29],"B-Cell Non-Hodgkin Lymphoma (NHL)","Richter's Transformation","T-Cell Non-Hodgkin Lymphoma","2026-08-07",{"date":99,"type":36},"2026-08-10",{"date":101,"type":36},"2026-08-05",{"date":103,"type":19},"2051-07",{"name":105,"class":42},"University of Pennsylvania",{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":20,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100333226","phase-2-phase-ii-study-of-second--line-pembrolizumab-plus-gvd-for-relapsed-or-refractory-hodgkin-lymphoma-100333226","NCT03618550","Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma","Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma","Inclusion Criteria:\n\n* Histologic diagnosis of classical Hodgkin's lymphoma. Primary refractory or relapsed disease proven by biopsy at enrolling institution.\n* Be willing and able to provide written informed consent\u002Fassent for the trial.\n* Be ≥ 18 years of age on day of signing informed consent.\n* PET scan before initiating pembro-GVD have measurable disease based on Lugano 2014 criteria\n* Have a performance status of 0 or 1 on the ECOG Performance Scale\n* Demonstrate adequate organ function as defined in table below\n* Demonstrate adequate organ function as defined in table below. Hematological\\*\n* Absolute neutrophil count (ANC) ≥1000 \u002FmcL\n* Platelets ≥50,000 \u002F mcL\n* Hemoglobin ≥8 g\u002FdL Renal\n* Serum creatinine OR ≤1.5 X upper limit of normal (ULN) OR\n* Measured or calculated creatinine clearance (eGFR can also be used in place of creatinine) ≥60 mL\u002Fmin for subject with creatinine levels \\> 1.5 X institutional ULN Hepatic\\*\n* Serum total bilirubin ≤ 1.5 X ULN OR ≤ 3 X ULN for subjects with liver metastases\n* AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases Pulmonary\n* Hemoglobin-adjusted diffusing capacity for carbon monoxide ≥50% (If unadjusted DLCO is \\>\u002F= 50% then there is no need to calculate adjusted) Cardiac\n* Ejection fraction ≥45% Coagulation\n* International normalized ratio (INR) OR prothrombin time (PT), Activated partial thromboplastin time (aPTT): ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants\n\n  \\*Lab values for eligibility should be based upon labs prior to Cycle 1 treatment of Pembro-GVD.\n* Female subject of childbearing potential should have a negative urine or serum pregnancy within 2 weeks prior to receiving the first dose of study medication. On the day of planned treatment, if a blood pregnancy test has not been performed within the two week window, a stat pregnancy test (urine or blood) should be performed and the results reviewed before treatment is begun.\n* Female subjects of childbearing potential must be willing to use an adequate method of contraception (see details in section 11.4.3).\n* Male subjects of childbearing potential must agree to use an adequate method of contraception.(see details in section 11.4.3).\n* HIV-infected participants must have well-controlled HIV on ART, defined as:\n\n  * Participants on ART must have a CD4+ T-cell count ≥350 cells\u002Fmm3 at the time of screening\n  * Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies\u002FmL or the LLOQ (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening\n  * It is advised that participants must not have had any AIDS-defining opportunistic infections within the past 12 months.\n  * Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before study entry (Day 1) and agree to continue ART throughout the study\n* Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible.\n\nExclusion Criteria:\n\n* Known pregnancy or breast-feeding.\n\n  * Breast-feeding should be discontinued prior to treatment initiation.\n* Medical illness unrelated to Hodgkin's Lymphoma, which, in the opinion of the attending physician and\u002For principal investigator, makes participation in this study inappropriate.\n* Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has known active HIV, Hepatitis B (e.g., Hepatitis B PCR positive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.\n* Has a history of pneumonitis related to PD-1 blockade that required steroids.\n* Has an active infection requiring systemic therapy.\n* Has not adequately recovered from major surgery or has ongoing surgical complications\n* Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Subjects who have had an allogeneic hematopoietic transplant greater than 5 years ago are eligible as long as there are no symptoms of GVHD.)\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",{"count":114,"type":19},257,[56],"The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.",[29,118],"Relapsed or Refractory Hodgkin Lymphoma",[120,121,122],"Pembrolizumab","GVD","18-160","2026-08-06",{"date":97,"type":36},{"date":126,"type":36},"2018-08-01",{"date":128,"type":19},"2027-08",{"name":130,"class":42},"Memorial Sloan Kettering Cancer Center",10,{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":16,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":20,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":43},"100446362","phase-1-phase-iii-study-of-car70--engineered-il15-transduced-cord-blood-derived-nk-cells-in-conjunction-with-lymphodepleting-chemotherapy-for-the-management-of-relapserefractory-hematological-malignances-100446362","NCT05092451","Phase I\u002FII Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Hematological Malignances","Inclusion criteria:\n\n1. Patients with hematological malignances with an expression of CD70 in the pre-enrollment tumor sample ≥ 10% measured by immunohistochemistry or flow cytometry.\n2. Patients must meet diseases specific eligibility criteria (see below)\n3. Patients at least 1 week from last cytotoxic chemotherapy at the time of starting lymphodepleting chemotherapy, except for Hydroxyurea which is allowed for peripheral blood count control in AML, CML, and MDS patients until the day prior to administration of lymphodepleting chemotherapy. Patients may continue tyrosine kinase inhibitors or other targeted therapies until up to three days prior to administration of lymphodepleting chemotherapy.\n4. Localized radiotherapy to one or more disease sites is allowed prior the infusion provided that there are additional disease sites that are not irradiated to assess response\n5. Karnofsky Performance Scale \\> 50% for patients who are \\>16 years old or Lansky score ≥50% for patients who are ≤16 years of age.\n6. Adequate organ function:\n\n   1. Renal: Serum creatinine \\\u003C\u002F= 2x ULN or estimated Glomerular Filtration Rate \\>\u002F= 30 ml\u002Fmin\u002F1.73 m2\n   2. Hepatic: ALT\u002FAST \\\u003C\u002F= 3 x ULN or \\\u003C\u002F= 5 x ULN if documented liver metastases, Total bilirubin \\\u003C\u002F2xULN, except in subjects with Gilbert's Syndrome in whom total bilirubin must be \\\u003C\u002F= 3 x.ULN. No history of liver cirrhosis. No ascites.\n   3. Cardiac: Cardiac ejection fraction \\>\u002F= 40%, no clinically significant pericardial effusion as determined by an ECHO, and no uncontrolled arrhythmias or symptomatic cardiac disease.\n   4. Pulmonary: No clinically significant pleural effusion (per PI discretion), baseline oxygen saturation \\> 92% on room air and adequate pulmonary function with FEV1, FVC and DLCO (corrected for Hgb) \\>50%.\n7. Able to provide written informed consent.\n8. 12-80 years of age.\n9. Weight ≥40 kg\n10. All participants who are able to have children must practice effective birth control while on study and up to 3 months post completion of study therapy. Acceptable forms of birth control for female patients include: hormonal birth control, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence, for the length of the study. If the participant is a female and becomes pregnant or suspects pregnancy, she must immediately notify her doctor. If the participant becomes pregnant during this study, she will be taken off this study. Men who are able to have children must use effective birth control while on the study. If the male participant fathers a child or suspects that he has fathered a child while on the study, he must immediately notify his doctor.\n11. Signed consent to long-term follow-up protocol PA17-0483 to fulfill the institutional responsibilities to various regulatory agencies.\n12. Are willing and able to provide informed consent, as appropriate (either directly or through a legally authorized representative \\[LAR\\])\n\nExclusion criteria:\n\n1. Positive beta HCG in female of child-bearing potential defined as not postmenopausal for 24 months or no previous surgical sterilization or lactating females.\n2. Presence of clinically significant Grade 3 or greater toxicity from the previous treatment, as determined by PI.\n3. Presence of uncontrolled fungal, bacterial, viral, or other infection not responding to appropriate therapy.\n4. HIV with detectable viral load\n5. Presence of active neurological disorder(s).\n6. Active autoimmune disease within 12 months of enrollment\n7. Amyloidosis or POEMS syndrome\n8. Active cerebral or meningeal involvement by the malignancy\n9. Active (defined as requiring therapy) acute or chronic GVHD\n10. Any other malignancy known to be active, except for treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.\n11. Presence of any other serious medical condition that may endanger the patient at investigator discretion.\n12. Major surgery \\\u003C4 weeks prior to first dose of the preparatory chemotherapy\n13. Allogeneic SCT or DLI \\\u003C12 weeks prior to first dose of preparatory chemotherapy\n14. Concomitant use of other investigational agents.\n15. Concomitant use of other anti-cancer agents.\n16. Patients receiving systemic steroid therapy at time of NK cell infusion (physiological substitutive doses are allowed), or have received antithymocyte globulin or lymphocyte immune globulin within 14 days of enrollment or alemtuzumab within 28 days of enrollment.\n17. Patients receiving immunosuppressive therapy","12 Years","80 Years",{"count":141,"type":19},80,[91,56],"The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma.\n\nImmune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.",[145,146,147,148,149,29,150,151,152,153],"B-Cell Lymphoma","Myelodysplastic Syndromes (MDS)","Acute Myeloid Leukemia (AML)","Multiple Myeloma","Plasma Cell Leukemia","T-cell Non-Hodgkin's Lymphoma\u002F T-cell Acute Lymphoblastic Leukmeia","Myelodysplastic Syndrome \u002F Chronic Myelomonocytic Leukemia","Blastic Transformation of Chronic Myeloid Leukemia","Germ Cell Tumors",{"date":97,"type":36},{"date":156,"type":36},"2022-11-01",{"date":158,"type":19},"2030-08-31",{"name":160,"class":42},"M.D. Anderson Cancer Center",{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":20,"phases":170,"briefSummary":171,"conditions":172,"keywords":175,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":43},"100523072","phase-1-atlcarcd30ccr4-for-cd30-hl-atlcarcd30ccr4-cells-100523072","NCT06090864","ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells","The Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed\u002FRefractory CD30+ Hodgkin s Lymphoma","During the period of cell procurement and lymphodepletion, subjects will be eligible to receive standard-of-care therapy e.g., chemotherapy or radiation therapy to stabilize their disease if the treating physician feels it is in the subject's best interests. Eligibility must be maintained up until the subject is procured, receives lymphodepletion, or receives treatment for the subject to be considered eligible to proceed with the specific phase of the study.\n\nInclusion Criteria:\n\nUnless otherwise noted, subjects must meet all of the following criteria to participate in all phases of the study. As these criteria are unchanging they will be evaluated at the time of initial enrollment and not continuously throughout the study.\n\n1. Written informed consent and HIPAA authorization for release of personal health information explained to, understood by, and signed by the subject or legally authorized representative.\n2. Age ≥ 18 years at the time of consent.\n3. Karnofsky score of \\> 60%\n4. The subject must have a diagnosis of Classical Hodgkin Lymphoma according to World Health Organization criteria.\n\nExclusion Criteria:\n\n1. Subjects had major surgery within 28 days.\n2. Subject received investigational agents or tumor vaccines within 3 weeks.\n3. Subject received chemotherapy or radiation therapy within the previous 3 weeks.",{"count":169,"type":19},31,[91,56],"Despite the progress in the therapy, Hodgkin's Lymphoma (HL) remains fatal for more than 15% of patients. Even in patients who are cured, the morbidity of therapy is substantial and long-lasting. New therapeutic agents are required therefore not only to further reduce mortality but also to alleviate morbidity.\n\nThe majority of HL express the CD30 antigens. CD30 expression is routinely used for the diagnosis of HL. Preclinical observations support CD30 as a viable target of CAR-T therapy. This phase Ib\u002FII study was conducted based on these observations.\n\nThe purpose of this study is to determine the tolerability of ATLCAR.CD30.CCR4 cells in subjects with Hodgkin's Lymphoma and identify a recommended dose for further.\n\nThis is a single-center, open-label phase Ib\u002FII trial that uses a 3+3 design to identify a recommended phase 2 dose (RP2D) of ATLCAR.CD30.CCR4 cells in Hodgkin's Lymphoma. The phase II portion is designed to determine the PFS of ATLCAR.CD30.CCR4 in Hodgkin's Lymphoma.\n\nSubjects will be enrolled on 1 of 3 dose levels as determined by a 3+3 design. Up to 25 evaluable subjects may then be enrolled in the phase II portion of the study. Subjects may have cells procured to manufacture the ATLCAR.CD30.CCR4 cells if they meet eligibility for procurement. During the time period necessary to manufacture the ATLCAR.CD30.CCR4 cells, Subjects will be allowed to receive standard-of-care bridging therapy at the discretion of their local oncologist. Prior to cell infusion, subjects will undergo additional eligibility evaluations, and then if eligible, will undergo lymphodepletion followed by cell infusion 2-14 days later. Subjects will then be followed for 15 years as is required for studies involving gene transfer experiments.",[29,173,174],"Relapse","Refractory",[176,177],"cellular therapy","CD30+","2026-08-03",{"date":123,"type":36},{"date":181,"type":36},"2024-04-25",{"date":183,"type":19},"2033-07-01",{"name":185,"class":42},"UNC Lineberger Comprehensive Cancer Center",{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":16,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":20,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":43},"100635353","phase-2-phase-2-study-of-nivolumab-plus-avd-in-pediatric-adolescent-and-young-adult-patients-with-chl-100635353","NCT07551583","Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL","A Phase 2 Single Arm Study To Evaluate Safety And Preliminary Efficacy Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With Newly Diagnosed Early-Stage Non-Bulky Classical Hodgkin Lymphoma","Inclusion Criteria:\n\n1. Age ≥ 2 year to 21 years\n2. Newly diagnosed early-stage (I\u002FII) non-bulky (\\\u003C10cm) classical Hodgkin lymphoma\n3. Baseline ejection fraction must be \\> 40%\n4. Adequate hepatic function (direct bilirubin \\\u003C 1.5x upper limit of normal (ULN) unless increase is due to Gilbert's disease or lymphoma involvement, and AST and\u002For ALT \\\u003C 3x ULN unless considered due to lymphoma involvement, in which case direct bilirubin \\\u003C 3x ULN or AST and\u002For ALT \\\u003C 5x ULN will be considered eligible)\n5. Adequate renal function (creatinine clearance ≥ 30 mL\u002Fmin) unless related to disease\n6. ECOG performance status ≤2 (Karnofsky ≥60%,) (See Appendices)\n7. In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 14 days for cytotoxic or non-cytotoxic (immunotherapy agent(s), or an interval of 5 half-lives of the prior therapy (whichever is shorter). Steroids for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the PI\n8. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better as classified by PI\n9. Unless surgically or biologically sterile: Women of childbearing potential must agree to adequate methods of contraception during the study and at least 3 months for males, and 6 months for females, after the last treatment\n\n   The effects of this combination of chemotherapy on the developing human fetus are unknown. For this reason, these agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n   * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n   * History of hysterectomy or bilateral salpingo-oophorectomy.\n   * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n   * History of bilateral tubal ligation or another surgical sterilization procedure.\n\n   Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n10. Ability to understand and the willingness to sign a written informed consent document as detailed below and if minor, getting parental\u002Fguardian consent\n\nExclusion Criteria:\n\n11\\) Patients who have received prior systemic therapy for the lymphoma with the exclusion of steroids for inflammatory conditions (e.g. asthma) or greater than 72 hours of emergent steroids (e.g. symptomatic mediastinal mass)\n\n1. Patients who weigh less than 10kg\n2. Any severe allergy to any of the drugs (Nivo-AVD)\n3. Patients with any concurrent uncontrolled medical condition, infection, laboratory abnormality, or psychiatric illness which could place the patient at unacceptable risk of study treatment\n4. Patients who are receiving any other cancer directed investigational agents; The use of other chemotherapeutic agents or anti-lymphoma agents is not permitted during study\n5. Active or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegener syndrome) within the past 2 years. Subjects with childhood atopy or asthma, vitiligo, alopecia, Hashimoto syndrome, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded\n6. Current or prior use of immunosuppressive medication within 14 days prior to the first dose of nivolumab. The following are exceptions to this criterion:\n\n   1. Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection).\n   2. The use of stable systemic steroid doses less than or equal to 20 mg of prednisone daily are permitted for medical conditions needing systemic steroids.\n   3. Steroids as premedication for hypersensitivity reactions (eg, computed tomography \\[CT\\] scan premedication\n\n12\\) The use of strong inhibitors or inducers of CYP1A2 (dacarbazine interaction) or CYP3A4 (doxorubicin, vinblastine interactions) should be avoided. Multiple CYP3A4 interacting agents of moderate or strong effect in the HIV+ patients should not be used. This includes most HIV protease inhibitors. 13) Known active HIV and hepatitis B and hepatitis C (unless see below points (a)(b)). Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Patients with prior hepatitis B and hepatitis C with are undetectable viral load are eligible for this trial.\n\n14\\) For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n\na. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n\n7\\) Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements 8) Patients with a concurrent active malignancy under treatment 9) Pregnant women are excluded from this study because these agents have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated on protocol","2 Years","21 Years",{"count":196,"type":19},15,[56],"The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult patients.\n\nThe safety of this drug combination will also be studied.",[29],"NOT_YET_RECRUITING","2026-07-28",{"date":203,"type":36},"2026-07-30",{"date":205,"type":19},"2026-10-01",{"date":207,"type":19},"2032-12-31",{"name":160,"class":42},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":20,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":43},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":217,"type":19},27,[56],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[221,222,223,224,225,226,227,228,229,230,231,232,233,234,29,235,236,237,238,239,148,240,241,242,243,244,245,246,247],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Bladder Carcinoma","Breast Carcinoma","Cervical Carcinoma","Colorectal Carcinoma","Endometrial Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Head and Neck Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Lung Carcinoma","Malignant Solid Neoplasm","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Myelodysplastic Syndrome","Ovarian Carcinoma","Pancreatic Carcinoma","Primary Peritoneal Carcinoma","Prostate Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma",{"date":203,"type":36},{"date":250,"type":36},"2025-12-18",{"date":252,"type":19},"2026-12-18",{"name":254,"class":42},"Mayo Clinic",{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":262,"sex":16,"minAge":87,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":20,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":286},"100594521","phase-1-a-vaccine-cmv-mva-triplex-vaccine-for-the-enhancement-of-cmv-specific-immunity-and-the-prevention-of-cmv-viremia-in-patients-undergoing-haploidentical-hematopoietic-stem-cell-transplant-100594521","NCT07020533","A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","A Phase 1b Trial of CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients of Hematopoietic Stem Cell Transplant","Inclusion Criteria:\n\n* DONORS: Documented informed consent of the participant. This can be done in person or informed consent can be obtained remotely.\n\n  * Remote consent, when appropriate, will be obtained per institutional guidelines.\n  * Assent, when appropriate, will be obtained per institutional guidelines.\n  * Adult subjects who require a legally authorized representative (LAR) will not be permitted to be enrolled under this protocol.\n* DONORS: Age: 18 - 75.\n* DONORS: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* DONORS: Agreement by females and males of childbearing potential\\* to use an effective method of birth control (hormonal or barrier method) or abstain from heterosexual activity prior to study entry and for up to 90 days post-vaccination.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only).\n* RECIPIENTS: Documented informed consent of the participant and\u002For legally authorized representative. This can be done in person or informed consent can be obtained remotely.\n\n  * Remote consent, when appropriate, will be obtained per institutional guidelines.\n  * Assent, when appropriate, will be obtained per institutional guidelines.\n  * Adult subjects who require a legally authorized representative (LAR) will not be permitted to be enrolled under this protocol.\n* RECIPIENTS: Participant must be willing to comply with study and\u002For follow-up procedures, including willingness to be followed for one year post-HCT.\n* RECIPIENTS: Age: 18 - 75.\n* RECIPIENTS: Planned peripheral blood stem cell (PBSC) or bone marrow (BM) HCT for the treatment of the following hematologic malignancies:\n\n  * Lymphoma (Hodgkin and Non-Hodgkin).\n  * Myelodysplastic syndrome.\n  * Acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia\u002Flymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood. Persistent lymphadenopathy on computed tomography (CT) or CT\u002Fpositron emission tomography(PET) scan without progression is allowed.)\n  * Acute myeloid leukemia in first or second remission.\n  * Chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase.\n  * Other hematologic malignancies judged appropriate by the clinical principal investigators (PIs), including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis. Patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excluded\\*\\*.\n\n    * Adult cases of multiple myeloma (MM) are excluded as HCT is not standard of care for MM and is only performed in very advanced cases with an associated high risk of relapse and non-relapse mortality (NRM). Adults with aplastic anemia are excluded because their standard management includes T cell depletion with agents such as antithymocyte globulin (ATG), which is not permissible on this protocol. Patients undergoing a second haploHCT are not eligible (patients who have undergone a previous autologous HCT are eligible).\n* RECIPIENTS: Patients receiving myeloablative (MA) or reduced intensity conditioning (RIC) are allowed.\n* RECIPIENTS: CMV seropositive.\n* RECIPIENTS: Eligible haploidentical donors will have 2-4 mismatches if human leukocyte antigen (HLA)-A, -B, -C, and -DRB1 typing is used; 2-5 mismatches if HLA-A, -B, -C, -DRB1, and -DQB1 typing is used; and 2-6 mismatches if HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 typing is used. A unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch. The donor and recipient must demonstrate that they are a full haplotype match by being identical at a minimum of one allele (at high resolution deoxyribonucleic acid \\[DNA\\]-based typing) at the following genetic loci: HLA-A, -B, -C, and DRB1 if 8 allele typing is used; HLA-A, -B, -C, -DRB1, and -DQB1 if 10 allele typing is used; and HLA-A, -B, -C, -DRB1-, DQB1, and -DPB1 is 12 allele typing is used.\n* RECIPIENTS: Planned HCT with minimal to no-T cell depletion of graft.\n* RECIPIENTS: Conditioning and immunosuppressive regimens according to institutional guidelines are permitted.\n* RECIPIENTS: Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Aspartate aminotransferase (AST) =\\\u003C 2.5 x ULN (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Alanine aminotransferase (ALT) =\\\u003C 2.5 x ULN (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Estimated creatinine clearance acceptable per institutional guidelines (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Left ventricular ejection fraction (LVEF) ≥ 50%.\n\n  * Note: To be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: If able to perform pulmonary function tests: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and carbon monoxide diffusing capability (DLCO) (diffusion capacity) ≥ 50% of predicted (corrected for hemoglobin).\n\n  * If unable to perform pulmonary function tests: Oxygen (O2) saturation \\> 92% on room air.\n  * Note to be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: Seronegative for HIV antigen (Ag)\u002Fantibody (Ab) combination (combo), hepatitis c virus (HCV)\\*, active hepatitis b virus (HBV) (surface antigen negative) and syphilis (RPR) within 2 months of registration and no history of disseminated cutaneous human papillomavirus (HPV) related disease.\n\n  * If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable.\n* RECIPIENTS: Meets other institutional and federal requirements for infectious disease titer requirements.\n\n  * Note Infectious disease testing to be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Agreement by females and males of childbearing potential\\* to use an effective method of birth control (hormonal or barrier method) or abstain from heterosexual activity prior to study entry and up to 90 days post-HCT.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only).\n\nExclusion Criteria:\n\n* DONORS: Any prior transplant to day 1 of protocol therapy (day 1 defined as the day after donors receive the Triplex vaccine).\n* DONORS: Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy.\n* DONORS: Receipt of any vaccine (licensed or investigational) within 30 days prior to and after the study vaccine.\n* DONORS: Unfit to undergo standard stem cell mobilization and apheresis e.g. abnormal blood counts, history of stroke, uncontrolled hypertension.\n* DONORS: Sickling hemoglobinopathy including hemoglobin (Hb)SS, HbAS, HbSC.\n* DONORS: Donors with impaired cardiac function are excluded. Electrocardiography is routine for potential HCT donors over 60 years old and those with a history of heart disease. Subjects in whom cardiac function is abnormal (excluding 1st degree branch block, sinus bradycardia, sinus tachycardia or non-specific T wave changes) are ineligible for Triplex vaccination.\n* DONORS: Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the donation procedure unlikely and making informed consent impossible.\n* DONORS: Females only: Pregnant or breastfeeding.\n* DONORS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n* DONORS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics).\n* RECIPIENTS: Any prior investigational CMV vaccine.\n* RECIPIENTS: Experimental anti-CMV chemotherapy in the last 6 months.\n* RECIPIENTS: Live attenuated vaccines (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Medically indicated subunit (Engerix-B for HBV; Gardasil for HPV) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Allergy treatment with antigen injections (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Alemtuzumab or any equivalent in vivo T-cell depleting agent (or CD34+ selection) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)\u002Fvalganciclovir (VAL), foscarnet (FOS), cidofovir, CMX-001, maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment EXCEPT letermovir prophylaxis (prior to day 100) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Disease-based radiation therapy (not total body irradiation) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Other investigational product(s) - concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Other medications that might interfere with the evaluation of the investigational product (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years.\n* RECIPIENTS: Patients considered by PI\u002Fconsenting physicians to have a complicated prior therapy or HCT regimen, or who have a low survival probability (e.g., refractory leukemia and\u002For undergoing 2nd HCT).\n* RECIPIENTS: Poor risk disease\u002Fdisease status including: Chronic myelogenous leukemia (CML) in blast crisis, acute myeloid leukemia (AML)\u002Facute lymphoblastic leukemia (ALL) beyond 2nd remission, multiple myeloma, and aplastic anemia.\n* RECIPIENTS: Females only: Pregnant or breastfeeding.\n* RECIPIENTS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n* RECIPIENTS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics).",true,"75 Years",{"count":265,"type":19},46,[91],"This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and\u002For effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.",[269,270,271,272,273,233,29,274,240,275,276,277],"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Chronic Lymphocytic Leukemia","Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Lymphoblastic Lymphoma","Myelofibrosis","Myeloproliferative Neoplasm","Non-Hodgkin Lymphoma","2026-07-27",{"date":201,"type":36},{"date":281,"type":36},"2026-05-08",{"date":283,"type":19},"2029-05-30",{"name":285,"class":42},"City of Hope Medical Center",3,{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":20,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":131},"100527661","phase-1-a-phase-1-of-ctx-8371-in-patients-with-advanced-malignancies-100527661","NCT06150664","A Phase 1 of CTX-8371 in Patients With Advanced Malignancies","A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed\u002Frefractory to standard therapy or for which no effective standard therapy is available, including\n\n   1. Malignant Melanoma (MM)\n\n      * Patients who have progressed after a minimum of 2 doses of a PD-1\u002FPD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1\u002FPD-L1 blocking antibody\n      * Patients must have had prior testing for BRAF V600 mutations. Patients with BRAF V600 activating mutation must have received prior therapy with a BRAF\u002FMEK inhibitor\n      * Uveal and mucosal melanoma are excluded\n   2. Head and Neck squamous cell carcinoma (HNSCC)\n\n      * HNSCC of oral cavity, oropharynx, hypopharynx, or larynx\n      * Patients who have progressed after a minimum of 2 doses of a PD-1\u002FPD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1\u002FPD-L1 blocking antibody\n      * Patients must have received prior treatment with platinum-based chemotherapy\n   3. Non-Small Cell Lung Cancer (NSCLC)\n\n      * Patients who have progressed after a minimum of 2 doses of a PD-1\u002FPD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1\u002FPD-L1 blocking antibody\n      * Patients must have received prior treatment with platinum-based chemotherapy\n   4. Triple Negative Breast Cancer (TNBC)\n\n      * ER\u002FPR and HER2 status should be defined by ASCO\u002FCAP guidelines (JCO Allison et al 2020)\n      * Patients with HER2-low cancers (HER2 IHC 1+ or 2+\u002FISH negative) are excluded\n      * Patients must have received prior sacituzumab govitecan and if PD-L1 ≥10% by CPS pembrolizumab with chemotherapy\n   5. Classical Hodgkin Lymphoma (HL)\n\n      * Patients must have received at least two prior systemic therapies including brentuximab vedotin (if eligible) and a prior PD-1 inhibitor\n      * Patients must have experienced less than a CR (according to Lugano criteria) to anti- PD-1 treatment\n   6. (Cohort 2 Dose Expansion): Non-Small Cell Lung Cancer (NSCLC)\n\n      * Patients who have progressed after a minimum of 2 doses of a PD-1\u002FPD-L1 treatment\n      * Patients must have received prior treatment with platinum-based chemotherapy\n   7. (Cohort 2 Dose Expansion) Triple Negative Breast Cancer (TNBC)\n\n      * ER\u002FPR and HER2 status should be defined by ASCO\u002FCAP guidelines (JCO Allison et al 2020)\n      * Patients must have received prior sacituzumab govitecan and if PD-L1 ≥10% by CPS pembrolizumab with chemotherapy\n      * Patients with HER2-low tumors (HER2 IHC 1+ or 2+\u002FISH negative) need to have received fam-trastuzumab deruxtecan (Enhertu)\n   8. (Cohort 2 Dose Expansion) Classical Hodgkin's Lymphoma (HL)\n\n      * Patients must have received at least two prior systemic therapies including brentuximab vedotin (if eligible) and a prior PD-1 inhibitor.\n      * Patients must have received at least 12 weeks of treatment with a PD-1\u002FPD-L1 inhibitor as a monotherapy or in combination and had at least stable disease or progressive disease (PD) with overall clinical benefit.\n3. Patients with NSCLC, MM, TNBC, and HNSCC must have measurable disease per RECIST 1.1. Patients with HL must have at least one measurable lesion \\> 1.5 cm for nodal, \\> 1.0 cm for extranodal FDG-avid disease by the Lugano (2014) response criteria. Tumor sites that are considered measurable must not have received prior radiation\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n5. Adequate bone marrow function defined by absolute neutrophil (ANC) of ≥ 1.5×109\u002FL, platelet count of ≥ 100.0×109\u002FL, and hemoglobin of ≥ 9.0 g\u002FdL (with or without transfusion)\n\n   a. (Cohort 2 Dose Expansion) Adequate bone marrow function defined by absolute neutrophil (ANC) of ≥ 1.5×109\u002FL, platelet count of ≥ 100.0×109\u002FL, and hemoglobin of ≥ 9.0 g\u002FdL (with or without transfusion) within 2 weeks from the first dose of CTX-8371.\n\n   \\- Blood transfusion is not allowed within 2 weeks from the first dose of CTX-8371\n6. Adequate hepatic function defined as serum total bilirubin ≤ 1.5 × ULN, AST\u002FALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases)\n7. Adequate renal function defined as creatinine clearance ≥ 30mL\u002Fmin by Cockcroft-Gault equation\n8. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commits to use 2 acceptable forms of birth control (defined as the use of an intrauterine device (IUD), a barrier method with spermicide, condoms, any form of hormonal contraceptives) or abstinence for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment\n9. Female patients who are women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening within 7 days of dosing with CTX-8371\n10. Last dose of previous PD-1 or PD-L1 therapy ≥ 28 days, other anticancer therapy \\> 21 days (or 2 half-lives for proteins, whichever is longer), radiotherapy \\>21 days (concurrent localized palliative radiotherapy is allowed during CTX-8371 treatment), or surgical intervention \\>21 days prior to the first dose of CTX-8371\n11. Resolution of all prior anti-cancer therapy toxicities ≤ Grade 2\n12. Life expectancy ≥ 12 weeks\n13. Capable of understanding and complying with protocol requirements\n14. Signed and dated institutional review board (IRB)\u002Findependent ethics committee (IEC)-approved informed consent form (ICF) before any protocol-directed screening procedures are performed\n\nExclusion Criteria:\n\n1. Developed clinically significant adverse reaction to PD-1 or PD-L1 therapy, including immune related adverse reactions, which led to discontinuation of treatment\n2. Systemic therapy with immunosuppressive agents within 7 days before the start of CTX-8371 treatment. Topical, intranasal, intraocular, or inhaled corticosteroids and physiologic replacement for patients with adrenal insufficiency are allowed\n3. Patient is a pregnant or lactating WOCBP\n4. Prior organ transplantation\n5. Patients with evidence of active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection. Patients with positive HBsAg and\u002For detectable HBV DNA are eligible only if adequately controlled on antiviral therapy according to institutional standards and liver function eligibility criteria are also met. HCV patients showing sustained viral response or patients with immunity to HBV infection may enroll.\n6. Active autoimmune disease or medical conditions requiring chronic steroid (i.e., \\> 10 mg\u002Fday prednisone or equivalent) or immunosuppressive therapy. Patients with a prior history of autoimmune disease may be eligible following discussion with the Medical Monitor\n7. History of primary malignancy other than the malignancy under study will be excluded, except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\>90%). Prior malignancy history will be evaluated on a case-by-case basis by the Sponsor Medical Monitor.\n8. Symptomatic or uncontrolled central nervous system and brain metastasis or active leptomeningeal disease. Patients with equivocal findings or with confirmed brain metastases are eligible for the study provided that they are asymptomatic and radiologically and neurologically stable without the need for corticosteroid treatment or seizure prophylaxis for ≥4 weeks before the first dose of study drug. Prior treatment with either surgery or radiation is permitted and all patients with a history of CNS or brain lesions require imaging during screening to confirm stability.\n9. Other medical condition that in the opinion of the Investigator and\u002For Sponsor Medical Monitor may interfere with the conduct and\u002For interpretation of the current study, including:\n\n   * Congestive heart failure (\\> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or clinically significant cardiac arrhythmias\n   * QTc interval (using Fridericia correction calculation) \\> 480 msec",{"count":295,"type":19},85,[91],"This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.",[299,300,29,301,302],"Non Small Cell Lung Cancer","Triple Negative Breast Cancer","Head and Neck Squamous Cell Carcinoma","Malignant Melanoma",{"date":201,"type":36},{"date":305,"type":36},"2024-03-19",{"date":307,"type":19},"2027-05",{"name":309,"class":310},"Compass Therapeutics","INDUSTRY",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":16,"minAge":318,"maxAge":263,"enrollmentInfo":319,"targetDuration":4,"studyType":20,"phases":321,"briefSummary":322,"conditions":323,"keywords":328,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":43},"100648944","phase-1-autologous-ic-nine-cd30-car-and-constitutive-il7r-expressing-ebvst-for-cd30-lymphoma-ancile-30-100648944","NCT07729397","Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)","ANCILE-30","Procurement Inclusion Criteria:\n\nParticipants must meet the protocol-defined procurement eligibility criteria before collection of peripheral blood mononuclear cells for manufacture of the investigational product, including:\n\n1. Diagnosis of relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma.\n2. CD30 positive tumor (can be pending at this time) as assayed in a CLIA certified Pathology Laboratory.\n3. Age 16 to 75 years.\n4. Hemoglobin ≥7.0(may be transfused value).\n5. Karnofsky or Lansky score of \\> 60%\n6. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given copy of informed consent.\n\nProcurement Exclusion Criteria:\n\n1. Active HIV or HTLV infection (testing may be pending at procurement).\n2. Active bacterial, fungal, or viral infection.\n\n   \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nTreatment Inclusion Criteria:\n\nParticipants with a successfully manufactured product must continue to satisfy the protocol-defined treatment eligibility criteria before receiving study treatment, including:\n\n1. Diagnosis and clinical course falling into one of the following categories:\n\n   * Hodgkin lymphoma\n   * CD30+ aggressive B-cell lymphoma\n   * ALK-negative anaplastic T cell lymphoma or other peripheral T- cell lymphoma\n   * ALK-positive anaplastic T cell lymphoma\n2. CD30 expression confirmed in a CLIA-certified laboratory. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy\n3. Age 16 to 75 years.\n4. Bilirubin ≤ 2 times the upper limit of normal (except for Gilbert syndrome, where the criteria will be Bilirubin ≤ 3 times the upper limit of normal).\n5. AST ˂ 3 times the upper limit of normal\n6. Estimated GFR \\> 50 mL\u002Fmin\n7. Pulse oximetry of \\> 90% on room air\n8. Karnofsky or Lansky score of \\> 60%\n9. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after study is concluded. Male partner should use a condom\n10. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002FGuardian given copy of informed consent.\n\nTreatment Exclusion Criteria:\n\n1. Received an investigational cell therapy or vaccine within the past 6 weeks.\n2. Received an investigational small molecule within the past 2 weeks.\n3. Received anti-CD30 antibody-based therapy within the previous 4 weeks.\n4. History of hypersensitivity reactions to murine protein-containing products\n5. Pregnancy or breastfeeding.\n6. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion)\n7. Current use of systemic corticosteroids at a dose equivalent to higher than 10 mg\u002Fday of prednisone.\n8. Active significant, uncontrolled bacterial, viral or fungal infection.\n9. Symptomatic cardiac disease (NYHA Class III or IV disease).","16 Years",{"count":320,"type":19},21,[91],"This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express a constitutively active IL7 receptor (C7R) and a chimeric antigen receptor (CAR) for CD30 (C7R.CD30-CAR-EBVSTs) in patients with relapsed or refractory CD30-positive lymphomas.\n\nParticipants who meet procurement eligibility criteria will undergo collection of peripheral blood mononuclear cells for manufacture of the investigational product. Participants with a successfully manufactured product who continue to meet treatment eligibility criteria will receive lymphodepleting chemotherapy followed by infusion of autologous C7R.CD30-CAR-EBVSTs.\n\nThe primary objective is to evaluate safety. Secondary and exploratory objectives include evaluation of antitumor effect, expansion and persistence of the infused cells, and the association between immunological parameters, safety, and clinical response.",[324,29,325,326,327],"Diffuse Large B-Cell Lymphoma (DLBCL)","Peripheral T-cell Lymphoma (PTCL)","Anaplastic Large Cell Lymphoma, ALK-Positive","Anaplastic Large Cell Lymphoma, ALK-Negative",[329,330,331,332,333,334,335,336,337,338,339],"CD30","Chimeric Antigen Receptor","CAR T Cells","Epstein-Barr Virus-Specific T Lymphocytes","EBVST","Constitutive IL7 Receptor","C7R","Gene Therapy","Cell Therapy","iC9","Inducible Caspase 9","2026-07-22",{"date":278,"type":36},{"date":343,"type":19},"2027-01-15",{"date":345,"type":19},"2044-02-28",{"name":347,"class":42},"The Methodist Hospital Research Institute",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":16,"minAge":138,"maxAge":263,"enrollmentInfo":356,"targetDuration":4,"studyType":20,"phases":358,"briefSummary":359,"conditions":360,"keywords":365,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":379},"100529662","phase-1-constitutive-il7r-c7r-modified-banked-allogeneic-cd30car-ebvsts-for-cd30-positive-lymphomas-100529662","NCT06176690","Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas","Constitutive IL7R (C7R) Modified Banked Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas","CABAL2","Inclusion Criteria:\n\n1. Diagnosis and clinical course falling into one of the following categories:\n\n   1. Hodgkin lymphoma\n   2. CD30+ aggressive B-cell lymphoma\n   3. ALK-negative anaplastic T cell lymphoma or other peripheral T- cell lymphoma\n   4. ALK-positive anaplastic T cell lymphoma\n2. CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory.\n3. Age 12 to 75.\n4. Bilirubin less than or equal to 2 times the upper limit of normal (except for Gilbert syndrome, where the criteria will be Bilirubin less than or equal to 3 times the upper limit of normal).\n5. AST less than 3 times the upper limit of normal.\n6. Estimated GFR \\> 70 mL\u002Fmin.\n7. Pulse oximetry of \\> 90% on room air\n8. Karnofsky or Lansky score of \\> 60%.\n9. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy.\n10. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.\n11. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form.\n\nExclusion Criteria:\n\n1. Received an investigational cell therapy or vaccine within the past 6 weeks.\n2. Received an investigational small molecule drug within the past 2 weeks.\n3. Received anti-CD30 antibody-based therapy within the previous 4 weeks.\n4. History of hypersensitivity reactions to murine protein-containing products.\n5. Pregnant or lactating.\n6. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion).\n7. Current use of systemic corticosteroids at a dose equivalent to or higher than 10 mg\u002Fday of prednisone.\n8. Active significant, uncontrolled bacterial, viral or fungal infection.\n9. Symptomatic cardiac disease (NYHA Class III or IV disease).",{"count":357,"type":19},90,[91],"This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer\u002FT-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not responded to treatment.\n\nPrevious research combined antibodies and T cells to treat cancer. Antibodies bind to foreign substances, and T cells are infection-fighting white blood cells that can kill tumor cells. Both approaches have shown promise but have not been sufficient to cure most patients. In prior studies, an antibody targeting CD30, a protein found on some T cells and cancer cells, was joined to T cells through gene transfer to create CD30.CAR T cells.\n\nAnother study showed encouraging responses using CD30.CAR T cells made from a patient's own blood and returned to the same patient (autologous cells). In an ongoing study, patients have been treated with CD30.CAR T cells derived from healthy donors (allogeneic cells), allowing use of banked cells without individualized manufacturing. This approach has shown promising clinical activity with no safety concerns to date.\n\nIn this study, investigators are evaluating CD30.CAR-EBVST cells modified with an additional molecule called C7R, which has been shown in laboratory studies to enhance anti-cancer effects. The study aims to assess the safety and effectiveness of these allogeneic, banked C7R-modified CD30.CAR-EBVST cells and determine whether they may help treat lymphoma.\n\nAs an added safety measure, the modified T cells include a marker called iC9. If significant side effects occur, patients may receive rimiducid, which can eliminate the infused T cells. Rimiducid is not yet FDA approved but has been tested in patients without significant side effects.",[361,362,326,363,364,277,29],"CD30-Positive Diffuse Large B-Cell Lymphoma","Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type","Peripheral T-cell Lymphoma","Anaplastic Large Cell Lymphoma, ALK-negative",[366,367,368,369],"CD30-Positive Lymphoma","Hodgkin lymphoma","non-Hodgkin lymphoma","CD30 CAR","2026-07-17",{"date":372,"type":36},"2026-07-20",{"date":374,"type":36},"2025-10-27",{"date":376,"type":19},"2043-06-27",{"name":378,"class":42},"Baylor College of Medicine",2,{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":16,"minAge":138,"maxAge":263,"enrollmentInfo":387,"targetDuration":4,"studyType":20,"phases":389,"briefSummary":390,"conditions":391,"keywords":401,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100647682","study-to-characterize-mismatched-to-fully-hla-matched-ossium-hpc-marrow-and-living-donor-transplantation-in-patients-with-hematologic-malignancies-100647682","NCT07710781","Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies","A Multicenter, Open Label Study to Evaluate the Efficacy, Tolerability, and Safety of Partially to Fully HLA-Matched Allogeneic Cryopreserved Deceased-Donor Bone Marrow Transplantation and Living Donor Transplantation in Patients With Hematologic Malignancies","Inclusion Criteria:\n\n1. Patient has the ability to provide informed consent according to the applicable regulatory and local institutional requirements.\n2. Male or female, aged ≥12 and ≤65 years for patients receiving MAC aged ≥12 and ≤75 years for patients receiving RIC. Patients between 75 and 80 years on RIC regimen can be enrolled with prior sponsor approval\n3. Patient must require first allogeneic HCT per the discretion of the treating physician\n4. BMI \\\u003C=50 (BMI of 45.1 to 50 maybe allowed after sponsor approval)\n5. For treatment from Ossium product only- no suitable donor available after 3 weeks of search\n6. Patient must be high-resolution:\n\n   1. HLA partially or fully matched (4-8\u002F8 allele matched at HLA-A, -B, -C, DRB1) to an available Ossium HPC, Marrow product for experimental arm\n   2. HLA fully matched (8\u002F8 allele matched at HLA-A, -B, -C, DRB1) to an unrelated available PBSC donor for observational standard of care arm\n   3. HLA partially matched (4-7\u002F8 allele matched at HLA-A, -B, -C, DRB1) to an available PBSC donor for observational standard of care arm\n   4. HLA haploidentical matched (4\u002F8 allele matched at HLA-A, -B, -C, DRB1) to available PBSC donor for observational standard of care arm\n   5. HLA partially matched (4-8\u002F8 allele matched at HLA-A, -B, -C, DRB1) to an available living bone marrow donor for optional observational standard of care arm\n7. Stated willingness to comply with all study procedures and availability for the duration of the study\n8. Patient with malignant hematologic disease including:\n\n   1. Diagnosed with acute leukemia \\[acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute biophenotypic leukemia (ABL), or acute undifferentiated leukemia (AUL)\\], , in the first remission or beyond with ≤5% marrow blasts and no circulating blasts or extra-medullary disease documented by bone marrow assessment within 42 days prior to anticipated start of conditioning or\n   2. MDS without Grade 3 fibrosis (Patients with Grade 1 and Grade 2 fibrosis can be enrolled with prior sponsor approval)\n   3. Chronic Lymphocytic Leukemia (CLL) eligible for allogeneic transplant or\n   4. Chronic Myeloid leukemia (CML) eligible for allogeneic transplant\n   5. Chemosensitive lymphomas in the first remission or beyond documented by PET\u002FCT imaging and bone marrow assessment within 42 days prior to anticipated start of conditioning\n   6. Other rare hematological malignancy indications eligible for allogenic transplant will require prior sponsor review and approval\n   7. Absence of active CNS disease due to underlying hematological disease\n9. Karnofsky performance status score ≥70% (MAC) or ≥60% (RIC)\n10. HCT comorbidity index (HCT-CI) ≤5\n11. Adequate organ function defined as:\n\n    1. Cardiac: LVEF at rest ≥40% (RIC) or LVEF at rest ≥45% (MAC)\n    2. Pulmonary: DLCO, FEV1, FVC ≥50% predicted by pulmonary function tests (PFTs). DLCO value may be corrected (dinakara correction) for hemoglobin.\n    3. Hepatic: total bilirubin ≤2.0 mg\u002FdL (except Gilbert syndrome ), and ALT, AST, and ALP \\\u003C3 x upper limit normal (ULN), unless ALT, AST, and\u002For ALP are disease related\n    4. Renal: CrCl\\> 45 mL\u002Fmin\u002F1.73m2 must be obtained (measured by 24-hour urine specimen or nuclear glomerular filtration rate (GFR), or calculated GFR (by Cockcroft-Gault formula)) or Cystatin-C test.\n\nExclusion Criteria:\n\n1. Autologous transplant within 6 months\n2. Prior allogeneic HCT\n3. Myeloproliferative disorders or MDS with grade 3 and higher fibrosis are excluded\n4. HTLV-ATLL positive patients are excluded\n5. Currently Pregnant or Currently lactating parent\n6. Participation with an investigational trial within 3 months of planned transplant (Note: participation in survey studies or standard of care studies maybe allowed after sponsors approval or are part of long term follow up for an interventional trial)\n7. Recipient of allogeneic CART-T therapy\n8. Recipient of checkpoint inhibitor in last 3 months\n9. Current uncontrolled bacterial, viral or fungal infection defined as currently taking medication with evidence of progression of clinical symptoms or radiologic findings\n10. Any condition(s) or diagnosis, both physical or psychological, or physical exam finding that in the investigator's opinion precludes participation\n11. Presence of donor-specific antibodies. Recipient has positive anti-donor HLA antibodies against a mismatched HLA in the selected donor determined by either:\n\n    1. positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) or\n    2. presence of donor specific HLA antibodies (DSA) to any mismatched HAS allele\u002Fantigen at any of the following loci (HLA-A, -B, -C, -DRB1, -DPA1, -DPB1) with median fluoresce intensity (MFI) \\>3000 by Luminex single antigen bead based solid phase immunoassay tested prior to SSA request and repeated if transplant is \\>30 days from prior HLA antibody testing or if patient receives additional blood products\u002Ftransfusion prior to transplant\n    3. Patients with donor specific HLA antibodies (DSA) to donor that is reduced post treatment of de-sensitization for DSA",{"count":388,"type":19},300,[22],"Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.",[392,393,270,271,394,395,396,397,398,399,29,400],"Hematologic Malignancy","Acute Leukemia","Acute Biphenotypic Leukemia","Acute Undifferentiated Leukemia","CLL (Chronic Lymphocytic Leukemia)","Chronic Myeloid Leukemia","MDS (Myelodysplastic Syndrome)","Non Hodgkin Lymphoma","Cutaneous T Cell Lymphomas (CTCL)",[402,403,16,404,405,406,407,408,60,409,410,411],"Leukemia","Hematologic Diseases","AML","ABL","AUL","Bone Marrow Transplant","Stem cell Transplant","MDS","CLL","CML","2026-07-16",{"date":372,"type":36},{"date":415,"type":19},"2026-12-01",{"date":417,"type":19},"2031-03-31",{"name":419,"class":310},"Ossium Health, Inc.",{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":263,"enrollmentInfo":426,"targetDuration":4,"studyType":20,"phases":427,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":43},"100605588","phase-2-phase-2-trial-of-cd70car-nk-cells-for-patients-with-primary-refractory-or-early-relapsed-diffuse-large-b-cell-lymphoma-and-hodgkin-lymphoma-100605588","NCT07164469","Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma","Inclusion Criteria:\n\n1. 18-75 years of age.\n2. Diagnosis of cHL or DLBCL that is either:\n\n   * Primary refractory, defined as not having achieved a CR with frontline therapy or having relapsed within 3 months.\n   * Early relapsed (≤ 12 months) after achieving a CR to frontline therapy.\n3. Tumor biopsy positive for CD70 \\>\u002F= 10% by immunohistochemistry or flow cytometry.\n4. Measurable disease, defined by one or more histologically confirmed hypermetabolic lesion on PET\u002FCT scan.\n5. ECOG PS ≤ 2 (Karnofsky ≥60%).\n6. Adequate blood counts (WBC \\> 2K, HGB \\> 8 g\u002FdL, platelets \\> 50K).\n7. Creatinine clearance ≥ 30 ml\u002Fmin.\n8. ALT and\u002For AST ≤ 3 x ULN, and bilirubin and ALP ≤ 2 x ULN.\n9. FEV1, FVC and DLCOc ≥ 50%.\n10. LVEF ≥40%, without active arrythmias.\n11. If female of child-bearing potential, she must not be pregnant or breastfeeding and is required to have a negative urine or serum pregnancy test prior to enrollment.\n12. For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n13. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n14. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n15. Patients with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n16. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.\n\n    To be eligible for this trial, patients should be class 2B or better.\n17. The effects of CAR-NK cells on the developing human fetus are unknown. For this reason and because fludarabine and cyclophosphamide, as well as other therapeutic agents used in this trial are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114).\n\n    * This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: Postmenopausal (no menses in greater than or equal to 12 consecutive months). History of hysterectomy or bilateral salpingo-oophorectomy. Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy). History of bilateral tubal ligation or another surgical sterilization procedure.\n    * Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n    * Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of CAR NK cell administration.\n18. Ability to understand and the willingness to sign a written informed consent document.\n19. Agree to sign consent to the long-term follow-up protocol PA17-0843 to fulfill the institutional responsibilities to various regulatory agencies.\n\nExclusion Criteria:\n\n1. Lymphoma in CR with no measurable sites of disease.\n2. Major surgery \\\u003C4 weeks prior to first dose of study drug.\n3. Any other severe or uncontrolled disease or condition which might increase the risk associated with study participation.\n4. Any other malignancy known to be active, with the exception of treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.\n5. Grade \\>\u002F= 3 non-hematologic toxicity from prior therapy that has not improved to grade \\\u003C\u002F= 2.\n6. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA\n\n   \\>\u002F=10,000 copies\u002FmL, or \\>\u002F=2,000 IU\u002FmL), or hepatitis C (detectable viral load by HCV RNA PCR).\n7. Active infection requiring parenteral antibiotics.\n8. HIV infection.\n9. Treatment within prior 2 weeks with any anti-cancer agent, investigational or approved.\n10. Active central nervous system (CNS) involvement (untreatedparenchymal brain metastasis or positive cytology of cerebrospinal fluid).\n11. Life expectancy \\\u003C\u002F= 6 months.\n12. Active and uncontrolled neurological disorder.\n13. Patients receiving systemic steroid therapy at time of enrollment (physiological replacement doses are allowed) or have received antithymocyte globulin or lymphocyte immune globulin within 14 days of enrollment or alemtuzumab within 28 days of enrollment.\n14. Patients receiving immunosuppressive therapy.",{"count":18,"type":19},[56],"This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.",[430,29],"Large B-cell Lymphoma","2026-07-14",{"date":433,"type":36},"2026-07-15",{"date":435,"type":19},"2026-12-28",{"date":437,"type":19},"2033-09-30",{"name":160,"class":42},{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":20,"phases":447,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":43},"100560657","phase-2-repurposing-riluzole-for-cancer-related-cognitive-impairment-a-pilot-trial-100560657","NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial","Inclusion Criteria:\n\n1. Cohort-specific inclusion for male and female patients.\n\n   a. Cohort A (no prior cranial radiation) i. Diagnosed with one of the following:\n   * Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and\u002For other breast cancer interventions.\n   * Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years.\n   * Non-breast cancer patients exposed to other anticancer therapies within the past 3 years.\n\n     b. Cohort B (prior cranial radiation)\n   * Previously received radiotherapy or radiosurgery to the brain for benign, malignant, or metastatic tumors.\n   * Life expectancy \\> 6 months\n2. Washout from investigational and conventional interventions is up to the discretion of the investigator. Concurrent participation in another intervention is allowable if judged by the Principal Investigator that this would not be scientifically or medically incompatible with this study.\n3. ≥18 years of age\n4. Perceived by patient or investigator that cognitive function has worsened since receipt of cranial radiation or cancer treatment.\n5. Able to provide informed consent.\n6. Literacy in English, Chinese, Korean, Vietnamese, or Spanish, to complete the questionnaires.\n7. Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes.\n\n   * Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.\n\nExclusion Criteria:\n\n1. Cohort-specific exclusion for male and female patients:\n\n   1. Cohort A (no prior cranial radiation)\n\n      * History of or current presence of primary brain tumors or brain metastases.\n   2. Cohort B (prior cranial radiation)\n\n      * Diagnosed with high grade glioma.\n2. Unwilling to undergo neuropsychological assessments necessary for the study.\n3. Women who are breastfeeding, pregnant or are planning to get pregnant during the study period. Persons of child-bearing potential (POCBP) must have a negative pregnancy test at screening if there is suspicion of pregnancy.\n\n   a. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n4. History of suspected hypersensitivity to riluzole or to any of its excipients.\n5. Patients taking or planned to take medications\u002Fsubstances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.\n6. Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)\n7. Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.",{"count":5,"type":19},[56],"This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.",[450,451,452,453,454,455,456,457,458,459,460,402,461,462,463,464,465,29,466,238,467,468],"Breast Cancer","Sarcoma","Gastric Cancer","Lung Cancer","Head and Neck Cancer","Colorectal Cancer","Ovarian Cancer","Liver Cancer","Genitourinary Cancer","Gynecologic Cancer","Urinary Bladder Cancer","Lymphoid Leukemia","Myeloma Multiple","Prostate Cancer","Pancreas Cancer","Non-hodgkin Lymphoma","Brain Cancer","Mycosis Fungoides","Kidney Cancer","2026-07-11",{"date":431,"type":36},{"date":472,"type":36},"2024-12-02",{"date":474,"type":19},"2027-12",{"name":476,"class":42},"University of California, Irvine",{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":16,"minAge":318,"maxAge":485,"enrollmentInfo":486,"targetDuration":4,"studyType":20,"phases":488,"briefSummary":490,"conditions":491,"keywords":492,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":505},"100415129","phase-3-brentuximab-vedotin-in-early-stage-hodgkin-lymphoma-100415129","NCT04685616","Brentuximab Vedotin in Early Stage Hodgkin Lymphoma","A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +\u002F- ISRT With A2VD +\u002F- ISRT in Patients With Previously Untreated Stage IA\u002FIIA Hodgkin Lymphoma","RADAR","Inclusion Criteria:\n\n* Males and females aged 16-69 years (inclusive) (age range is 18-69 in US and EU)\n* Histologically confirmed classical Hodgkin lymphoma\n* Stage I or II supradiaphragmatic disease with no mediastinal bulk disease (defined as greater than a third of the transthoracic diameter at any level of thoracic vertebra as determined by CT) or B symptoms. Bulky disease at other sites is acceptable. Extranodal disease (single extranodal site (stage I) or contiguous nodal extension (stage II)) is acceptable.\n* ECOG performance status 0-2.\n* No previous treatment for Hodgkin lymphoma\n* Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%)\n* Creatinine clearance (measured or calculated \\>40ml\u002Fmin\n* Total bilirubin \\\u003C1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome\n* ALT or AST \\\u003C 2 x upper limit of normal\n* Adequate bone marrow function with neutrophils ≥1.0x10\\^9\u002Fl and platelets ≥100x10\\^9\u002Fl\n* Haemoglobin ≥8g\u002FdL\n* Willing and able to comply with the requirements of the protocol, including contraceptive advice, where applicable\n* Written informed consent\n\nExclusion Criteria:\n\n* Previous treatment for Hodgkin lymphoma, excluding short courses of oral corticosteroids at a dose of 100mg prednisolone (or equivalent) for up to 7 days\n* Infradiaphragmatic disease\n* Nodular lymphocyte predominant Hodgkin lymphoma\n* Absence of FDG-avid lesions on baseline PET scan\n* Age 70 years or over or age 15 years or under\n* Other cancer diagnosed with the last 5 years. Patients with completely excised carcinoma in situ of any type and basal or squamous cell carcinoma of the skin are not excluded\n* Recurrent or persistent other cancer within last 5 years irrespective of date of initial diagnosis\n* Pre-existing grade ≥1 sensory or motor neuropathy from any cause\n* History of or current progressive multi-focal leukoencephalopathy or other chronic condition of the brain\n* Symptomatic neurologic disease compromising normal activities of daily living or requiring medications\n* Infection with HIV, hepatitis C or active hepatitis B infection (surface antigen or DNA positive)\n* Any active systemic viral, bacterial or fungal infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first trial drug dose\n* Receiving or recently treated with any other investigational agent (within 4 weeks of trial entry)\n* Pregnant or breastfeeding women\n* Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD\n* Known history of any cardiovascular or respiratory conditions that would preclude anthracycline or bleomycin administration\n* Other significant medical or psychiatric comorbidity that in the opinion of the investigator would make administration of ABVD or A2VD hazardous","69 Years",{"count":487,"type":19},1042,[489],"PHASE3","RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia\u002FNew Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry.\n\nEligible patients will be randomised to receive either ABVD or A2VD chemotherapy.\n\nAn interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation.\n\nPatients will be followed up for a minimum of 5 years after treatment.",[29],[493,494,495],"PET-response adapted","Stage IA\u002FIIA Hodgkin lymphoma","Brentuximab vedotin","2026-07-06",{"date":498,"type":36},"2026-07-08",{"date":500,"type":36},"2022-04-14",{"date":502,"type":19},"2032-09",{"name":504,"class":42},"University College, London",72,{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":515,"phases":4,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":542},"100159702","a-multicenter-access-and-distribution-protocol-for-unlicensed-cryopreserved-cord-blood-units-cbus-100159702","NCT01351545","A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)","A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications","Inclusion Criteria:\n\n* Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment\n* Signed informed consent (and signed assent, if applicable) obtained prior to study enrollment\n* Pediatric and adult patients of any age\n\nExclusion Criteria:\n\n* Patients who are receiving only licensed CBUs\n* Cord blood transplant recipients at international transplant centers\n* Patients who are enrolled on another IND protocol to access the unlicensed CBU(s)\n* Patients whose selected unlicensed CBU(s) will be more than minimally manipulated",{"count":514,"type":19},99999,"OBSERVATIONAL","This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.",[518,519,520,521,522,523,524,525,526,527,29,465,528,529,530,531,532],"Hematologic Malignancies","Inherited Disorders of Metabolism","Inherited Abnormalities of Platelets","Histiocytic Disorders","Acute Myelogenous Leukemia (AML or ANLL)","Acute Lymphoblastic Leukemia (ALL)","Other Acute Leukemia","Chronic Myelogenous Leukemia (CML)","Myelodysplastic (MDS) \u002F Myeloproliferative (MPN) Diseases","Other Leukemia","Multiple Myeloma\u002F Plasma Cell Disorder (PCD)","Inherited Abnormalities of Erythrocyte Differentiation or Function","Disorders of the Immune System","Autoimmune Diseases","Severe Aplastic Anemia","2026-07-01",{"date":496,"type":36},{"date":536,"type":4},"2011-10",{"date":538,"type":19},"2041-10",{"name":540,"class":541},"Center for International Blood and Marrow Transplant Research","NETWORK",142,{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":263,"enrollmentInfo":549,"targetDuration":4,"studyType":20,"phases":551,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":43},"100627130","phase-1-phase1-basket-trial-of-car70-engineered-il15-transduced-with-tgfbr2-knock-out-cord-blood-derived-nk-cells-for-relapsedrefractory-lymphoid-malignancies-100627130","NCT07444632","Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed\u002FRefractory Lymphoid Malignancies","Inclusion Criteria:\n\n1. 18-75 years of age.\n2. Diagnosis of relapsed B-NHL, HL, T-NHL, or B-ALL in refractory relapse, defined as:\n\n   * B-NHL: Failure of \\>\u002F= 1 salvage line and failure of or ineligibility for CAR-T.\n   * HL and T-NHL: Failure of \\>\u002F= 1 salvage line or prior SCT.\n   * ALL: Active disease (\\>5% of blasts or positive MRD at a level of \\>0.1% measured by multiparameter flow cytometry) after ≥ 2 two lines of therapy. Patients with B-ALL must have either failed of or be ineligible for CAR-T cell therapy. Patients who have mutations for which there are FDA approved targeted therapies (i.e., BCR-ABL) must also have received at least one of such agents.\n3. Expression of CD70 in the pre-enrollment sample \\>\u002F= 20% measured by immunohistochemistry or flow cytometry.\n4. Measurable disease, defined by \\>\u002F= 1 histologically confirmed hypermetabolic lesion on PET\u002FCT scan.\n5. ECOG PS ≤ 2 (Karnofsky ≥60%).\n6. Adequate blood counts (WBC \\>\u002F= 2K, HGB \\>\u002F= 8 g\u002FdL, platelets \\>\u002F= 50K).\n7. Creatinine clearance ≥ 30 ml\u002Fmin.\n8. ALT and\u002For AST ≤ 3 x ULN, and bilirubin and ALP ≤ 2 x ULN.\n9. FEV1, FVC and DLCOc ≥ 50%.\n10. LVEF ≥ 40%, without active arrythmias.\n11. If female of child-bearing potential, she must not be pregnant or breastfeeding and required to have a negative urine or serum pregnancy test prior to enrollment.\n12. For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n13. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection still on treatment, they are eligible if they have an undetectable HCV viral load.\n14. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n15. Patients with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n16. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n17. The effects of CAR-NK cells on the developing human fetus are unknown. For this reason and because fludarabine and cyclophosphamide, as well as other therapeutic agents, used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence, see Appendix 1) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114).\n\n    * This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n    * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n    * History of hysterectomy or bilateral salpingo-oophorectomy.\n    * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received whole pelvic radiation therapy).\n    * History of bilateral tubal ligation or another surgical sterilization procedure.\n    * Approved methods of birth control (see Appendix 1) are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal ligation or hysterectomy, subject\u002Fpartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide.\n\n    Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n\n    • Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of CAR NK cell administration.\n18. Ability to understand and willingness to sign a written informed document.\n19. Agree to sign consent to the long-term follow-up protocol PA17-0483 to fulfill the institutional responsibilities to various regulatory agencies.\n\nExclusion Criteria:\n\n1. Lymphoma or ALL in CR with no measurable sites of disease.\n2. Major surgery \\\u003C4 weeks prior to first dose of study drug.\n3. Any other severe or uncontrolled disease or condition which mightincrease the risk associated with study participation.\n4. Any other malignancy known to be active, with the exception of treated cervical intraepithelial neoplasia and non-melanoma skincancer.\n5. Grade \\>\u002F= 3 non-hematologic toxicity from prior therapy that has notimproved to grade \\\u003C\u002F= 2.\n6. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA \\>\u002F=10,000 copies\u002FmL, or \\>\u002F=2,000 IU\u002FmL), or hepatitis C (detectable viral load by HCV RNA PCR).\n7. Active infection requiring parenteral antibiotics.\n8. HIV infection.\n9. Treatment within prior 2 weeks with any anti-cancer agent,investigational or approved.\n10. Active CNS involvement (untreatedparenchymal brain metastasis or positive cytology of cerebrospinal fluid).\n11. Life expectancy \\\u003C\u002F= 6 months.\n12. Active and uncontrolled neurological disorder.\n13. Patients receiving systemic steroid therapy at time of enrollment (physiological replacement doses are allowed) or have received antithymocyte globulin or lymphocyte immune globulin within 14 days of enrollment or alemtuzumab within 28 days of enrollment.\n14. Patients receiving immunosuppressive therapy.\n15. Patients who are receiving any other investigational agents.\n16. Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":550,"type":19},60,[91],"This is a phase 1 basket trial of TGFBR2 KO CAR27\u002FIL-15 NK cells after lymphodepleting chemotherapy for patients with R\u002FR B-NHL, HL, T-NHL or B-ALL.",[554,29],"Lymphoid","2026-06-23",{"date":557,"type":36},"2026-06-26",{"date":559,"type":36},"2026-05-28",{"date":561,"type":19},"2032-09-30",{"name":160,"class":42},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":16,"minAge":138,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":20,"phases":573,"briefSummary":574,"conditions":575,"keywords":579,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":592},"100526622","phase-1-azd3470-as-monotherapy-or-in-combination-with-anticancer-agents-in-participants-with-haematologic-malignancies-100526622","NCT06137144","AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","A Modular Phase I\u002FII, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies","PRIMAVERA","Inclusion Criteria:\n\nCore Inclusion criteria:\n\n1. Adequate adult (ECOG) or adolescent (Karnofsy or Lanksy) Performance Score assessments\n2. Adequate organ and bone marrow function.\n\nModule 1 Cohort 1:\n\n1. Age:\n\n   1. Part A (dose escalation): aged ≥ 18 years at the time of signing the informed consent.\n   2. Part B (optimization): aged ≥ 12 years of age. Adolescent participants must weigh ≥ 40 kg.\n2. Histologically confirmed diagnosis of cHL based on WHO criteria\n3. Previous treatment with at least 2 prior lines of therapy for the treatment of cHL (including at least 2 cycles of BV and anti-PD1) and have documented r\u002Fr active disease requiring treatment.\n4. Participants must provide FFPE baseline tumour tissue.\n5. At least 1 radiographically measurable, and\u002For FDG-avid lymphoma lesion ( \\>1.5 cm for nodal lesion and \\>1 cm for extranodal lesion).\n\nModule 1 Cohort 2:\n\n1. Participants must be at least 50 years of age or older at study entry.\n2. Histologically confirmed diagnosis of cHL based on WHO criteria\n3. Ann Arbor stages III or IV.\n4. Participant must have previously received at least 4 cycles of SoC combination therapy with A-AVD, N-AVD, AVD, or ABVD (based on regional SOC, per investigator) as finite first-line induction therapy, and achieved at least a PR post-induction therapy.\n5. Participants must provide FFPE baseline tumour tissue.\n\nModule 1 Cohort 3:\n\n1. Participants must be aged ≥ 18 years at the time of signing the informed consent.\n2. Histologically confirmed diagnosis of PTCL NOS, systemic ALCL, or AITL based on WHO criteria.\n3. Participants must have received at least 1 prior line of therapy for the treatment of PTCL and have exhausted all available therapies with demonstrated clinical benefit. Participants with ALCL must have received prior BV treatment.\n4. Participants must provide FFPE baseline tumour tissue\n\n   a. Ability to provide an on-treatment biopsy (if the tumour is suitable for biopsy).\n5. At least 1 radiographically measurable, and\u002For FDG-avid lymphoma lesions (\\> 1.5 cm for nodal lesion and \\>1 cm for extranodal lesion).\n\nModule 2 Cohort 1:\n\n1. Participants must be aged ≥ 18 years at the time of signing the informed consent.\n2. Histologically confirmed diagnosis of cHL based on WHO criteria\n3. At least 1 radiographically measurable, and\u002For FDG-avid lymphoma lesions (\\> 1.5 cm for nodal lesion and \\>1 cm for extranodal lesion).\n4. Participant must have received at least 1 prior line of therapy for the treatment of cHL and have documented r\u002Fr active disease requiring treatment.\n5. Participants must provide FFPE baseline tumour tissue.\n\nExclusion Criteria:\n\nCore Exclusion criteria:\n\n1. Any significant laboratory finding or any severe and uncontrolled medical condition.\n2. Active CNS involvement by lymphoma, leptomeningeal disease, or spinal cord compression.\n3. Serologic active HBV or HCV infection.\n4. Known to have tested positive for HIV.\n5. Active gastrointestinal disease or other condition that will interfere with oral therapy.\n6. Any of the following ECG cardiac criteria: Mean resting QTcF \\> 470 msec, clinically important abnormalities in rhythm, conduction or morphology, and\u002For any factors that increase the risk of QTc prolongation or risk of arrhythmic events.\n7. Undergone any of the following procedures within 6 months prior to first dose:\n\n   1. Coronary artery bypass graft,\n   2. Percutaneous coronary intervention or heart valve replacement or repairment,\n   3. Vascular stent implantation (venous stent is eligible),\n   4. Acute coronary syndrome \u002F myocardial infarction,\n   5. Unstable or poorly controlled angina pectoris,\n   6. Ventricular arrhythmias requiring continuous therapy,\n   7. Uncontrolled atrial fibrillation,\n   8. Haemorrhagic or thrombotic stroke (including transient ischaemic attacks) or any other CNS bleeding.\n   9. Acute venous or atrial thromboembolic event (unless considered stable or adequately treated with at least 3months of therapeutic anticoagulation).\n8. Severe valvular heart disease.\n9. Congestive heart failure Grade II to Grade IV.\n10. Prior or current cardiomyopathy.\n11. Uncontrolled hypertension.\n12. History of significant haemoptysis or haemorrhage within4 weeks of the first dose of study treatment.\n13. Unresolved toxicities of Grade \\> 1 from prior anti cancer therapy (excluding peripheral neuropathy, vitiligo, alopecia and endocrine disorders that are controlled with replacement hormone therapy, and asymptomatic laboratory abnormalities), unless immune-mediated.\n14. History of another primary malignancy.\n15. Received the following anticancer therapies: anti-lymphoma therapy (within 21 days), radiation therapy(within 28 days), allo-HSCT (within 180 days), auto-HSCT\u002Fcellular therapy (within 60 days), or MAT2A or PRMT5 inhibitor\n16. Requires ongoing immunosuppressive therapy, including systemic corticosteroids.\n\nModule 2 Cohort 1:\n\n1. History of confirmed ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment or any evidence of clinically active ILD or pneumonitis.\n2. ≥Grade 3 immune-mediated AE while receiving prior checkpoint inhibitor immunotherapy, or any unresolved ≥Grade 2 immune-mediated AE.\n3. History of immune-mediated myocarditis or pericarditis.\n4. Experienced a toxicity that led to permanent discontinuation of prior immunotherapy.\n5. Active or prior documented pathologically confirmed autoimmune or inflammatory disorders\n6. Refractory to prior checkpoint inhibitor therapy (within 12 weeks of last dose)\n7. Eligible for allogeneic or autologous stem cell transplant.\n8. Received an allogeneic HSCT within 5 years of the first dose of study treatment; must not have active Graft-versus-host disease.\n9. Participants with a known hypersensitivity to pembrolizumab or any of the excipients of the product.",{"count":572,"type":19},161,[91,56],"This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.",[60,277,29,325,576,577,578],"PTCL-NOS","ALCL","AITL",[580,367,581,582,583],"Haematologic Malignancies","Peripheral T-cell lymphoma (PTCL)","Methylthioadenosine Phosphorylase (MTAP) deficient","Protein Arginine Methyltransferase 5 (PRMT5)",{"date":585,"type":36},"2026-06-24",{"date":587,"type":36},"2024-01-23",{"date":589,"type":19},"2029-05-03",{"name":591,"class":310},"AstraZeneca",37,{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":515,"phases":4,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":613},"100516308","evaluating-the-impact-of-social-and-genetic-factors-on-outcomes-in-adolescent-and-young-adult-cancer-survivors-100516308","NCT06002828","Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors","Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Patient must be \\>= 18 years of age at the time of registration\n* Patient must have been between the ages of 15-39 at the time of their first primary cancer diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma (NHL)\n* Patient must have completed therapy (with a complete response, per clinician determination) at the time of registration\n* Patients last date of prior systemic therapy for first primary diagnosis for Hodgkin lymphoma or non-Hodgkin lymphoma must have been within one year prior to registration\n\n  * NOTE: Systemic therapy refers to all anti-cancer therapy, including but not limited to chemotherapy, intravenous (IV) or oral targeted medications, or radiation, and administered via a clinical trial or standard approach\n* Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3\n* Patient must be English speaking in order to be able to complete the required QOL forms on this study\n\n  * NOTE: Sites cannot translate the associated QOL forms\n* Patient must not be receiving active therapy for Hodgkin lymphoma or non-Hodgkin lymphoma\n* Patient must have internet access through computer, tablet, or smartphone\n* Patient must have email address\n* Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available will also be considered eligible",{"count":601,"type":19},2000,"This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.",[29,277],"2026-06-16",{"date":606,"type":36},"2026-06-18",{"date":608,"type":36},"2023-10-13",{"date":610,"type":19},"2030-02-01",{"name":612,"class":541},"ECOG-ACRIN Cancer Research Group",428,{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":515,"phases":4,"briefSummary":623,"conditions":624,"keywords":665,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":43},"100289631","familial-investigations-of-childhood-cancer-predisposition-100289631","NCT03050268","Familial Investigations of Childhood Cancer Predisposition","SJFAMILY","NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown below, you may enroll regardless of the results of your clinical genetic testing.\n\nDEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL:\n\nIn this protocol, the definition of \"Familial Cancer\" is met if any of the following is present:\n\n* An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR\n* An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR\n* An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR\n* An individual with a congenital cancer diagnosed before 6 months of age; OR\n* An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age\n\nº Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer occurring in adults.\n\nINCLUSION CRITERIA:\n\n* An individual who meets this protocol's definition of \"Familial Cancer,\" as above.\n* Biologic relatives of an individual meeting this protocol's definition of \"Familial Cancer,\" who are either affected or unaffected by cancer.\n\nEXCLUSION CRITERIA:\n\n* An inability or unwillingness of the research participant or his\u002Fher legally authorized representative (LAR) to provide written informed consent.\n* The participant has received allogeneic bone marrow transplantation and has NO pre-transplant germline (cancer-unaffected) DNA available AND is unwilling to provide a skin sample.",{"count":622,"type":19},1500,"NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown in the Eligibility Section, you may enroll regardless of the results of your clinical genetic testing.\n\nWhile it is well recognized that hereditary factors contribute to the development of a subset of human cancers, the cause for many cancers remains unknown. The application of next generation sequencing (NGS) technologies has expanded knowledge in the field of hereditary cancer predisposition. Currently, more than 100 cancer predisposing genes have been identified, and it is now estimated that approximately 10% of all cancer patients have an underlying genetic predisposition.\n\nThe purpose of this protocol is to identify novel cancer predisposing genes and\u002For genetic variants. For this study, the investigators will establish a Data Registry linked to a Repository of biological samples. Health information, blood samples and occasionally leftover tumor samples will be collected from individuals with familial cancer. The investigators will use NGS approaches to find changes in genes that may be important in the development of familial cancer. The information gained from this study may provide new and better ways to diagnose and care for people with hereditary cancer.\n\nPRIMARY OBJECTIVE:\n\n* Establish a registry of families with clustering of cancer in which clinical data are linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues from the proband and other family members.\n\nSECONDARY OBJECTIVE:\n\n* Identify novel cancer predisposing genes and\u002For genetic variants in families with clustering of cancer for which the underlying genetic basis is unknown.",[393,625,626,404,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,29,644,645,646,409,647,648,649,650,651,652,653,399,654,655,656,657,658,659,660,661,26,662,663,664],"Adenomatous Polyposis","Adrenocortical Carcinoma","BAP1 Tumor Predisposition Syndrome","Carney Complex","Choroid Plexus Carcinoma","Constitutional Mismatch Repair Deficiency Syndrome","Diamond-Blackfan Anemia","DICER1 Syndrome","Dyskeratosis Congenita","Emberger Syndrome","Familial Acute Myeloid Leukemia","Familial Adenomatous Polyposis","Fanconi Anemia","Familial Cancer","Familial Wilms Tumor","Familial Neuroblastoma","GIST","Hereditary Breast and Ovarian Cancer","Hereditary Paraganglioma-Pheochromocytoma Syndrome","Juvenile Polyposis","Li-Fraumeni Syndrome","Lynch Syndrome","Melanoma Syndrome","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Neuroblastoma","Neurofibromatosis Type 1","Neurofibromatosis Type II","Nevoid Basal Cell Carcinoma Syndrome","Noonan Syndrome and Other Rasopathy","Overgrowth Syndromes","Pancreatic Cancer","Peutz-Jeghers Syndrome","Pheochromocytoma\u002FParaganglioma","PTEN Hamartoma Tumor Syndrome","Retinoblastoma","Rhabdoid Tumor Predisposition Syndrome","Rothmund-Thomson Syndrome","Tuberous Sclerosis","Von Hippel-Lindau Disease",[666,667,668,669,670,671,672,673,674],"Familial cancer","Genetic predisposition","Heritable disease","Cancer risk","Genome analysis","Genetic modifiers","Next generation sequencing (NGS)","Genetic counseling","DNA","2026-06-15",{"date":677,"type":36},"2026-06-17",{"date":679,"type":36},"2017-04-06",{"date":681,"type":19},"2037-03-31",{"name":41,"class":42},{"id":684,"slug":685,"hasResults":12,"nctId":686,"briefTitle":687,"officialTitle":688,"acronym":4,"eligibilityCriteria":689,"healthyVolunteers":12,"sex":16,"minAge":690,"maxAge":87,"enrollmentInfo":691,"targetDuration":4,"studyType":20,"phases":693,"briefSummary":694,"conditions":695,"keywords":4,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":697,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":703,"locationsCount":43},"100643612","phase-1-pd-1-antibody-and-jak1-inhibitor-for-newly-diagnosed-pediatric-hodgikins-lympoma-100643612","NCT07641010","PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma","A Prospective, Multicenter, Randomized Controlled Clinical Study of Camrelizumab in Combination With Ivarmacitinib as First-line Treatment for Pediatric Classical Hodgkin Lymphoma","Inclusion Criteria:\n\n1. Age 6-18 years, male or female;\n2. Histologically confirmed classic Hodgkin lymphoma;\n3. Newly diagnosed, previously untreated patients;\n4. Subjects must have at least one measurable lesion, defined as: a lymph node lesion with the longest diameter \\>1.5 cm on CT cross-sectional imaging; or an extranodal lesion with the longest diameter \\>1.0 cm;\n5. ECOG performance status (PS) 0-2;\n6. Life expectancy ≥3 months;\n7. All screening laboratory tests must be performed as required by the protocol and within 7 days prior to enrollment. The laboratory values obtained at screening must meet the following criteria:\n8. Hematology (without blood transfusion, G-CSF, or medication to correct abnormalities within 14 days prior to screening):\n\n   * Hemoglobin (Hb) ≥70 g\u002FL;\n   * Absolute neutrophil count (ANC) ≥0.5×10⁹\u002FL;\n   * Platelet count (PLT) ≥30×10⁹\u002FL;\n9. Biochemistry:\n\n   * Direct bilirubin (DBIL) \\\u003C2 × upper limit of normal (ULN);\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN;\n   * Serum creatinine clearance ≥40 mL\u002Fmin;\n10. The patient or his\u002Fher legal guardian has signed the informed consent form (ICF) and voluntarily agrees to participate in this study.\n\nExclusion Criteria:\n\n1. Histopathologically confirmed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL);\n2. Prior anti-tumor therapy for classic Hodgkin lymphoma (cHL);\n3. Patients with central nervous system (CNS) involvement by lymphoma;\n4. Inability to swallow oral medication, or any other factor affecting oral drug administration and absorption;\n5. Presence of any active, known, or suspected autoimmune disease (subjects who are in a stable condition and do not require systemic immunosuppressive therapy are permitted to enroll);\n6. Use of immunosuppressive agents, including systemic corticosteroids, within 14 days prior to study drug administration (use of ≤10 mg\u002Fday prednisone or equivalent is permitted);\n7. History of other malignancies within the past 5 years;\n8. Severe cardiac dysfunction with ejection fraction (EF) \\\u003C50%, or severe cardiac arrhythmia;\n9. Any arterial thromboembolic event within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack;\n10. Active hepatitis B or hepatitis C infection;\n11. History of stroke or intracranial hemorrhage within the past 6 months;\n12. Known history of human immunodeficiency virus (HIV) positivity.","6 Years",{"count":692,"type":19},112,[91,56],"A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma",[29],"2026-06-10",{"date":698,"type":36},"2026-06-11",{"date":700,"type":19},"2026-06-30",{"date":702,"type":19},"2030-09-30",{"name":704,"class":42},"Shanghai Jiao Tong University School of Medicine",{"id":706,"slug":707,"hasResults":12,"nctId":708,"briefTitle":709,"officialTitle":710,"acronym":4,"eligibilityCriteria":711,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":712,"targetDuration":4,"studyType":20,"phases":714,"briefSummary":715,"conditions":716,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":717,"startDateStruct":719,"completionDateStruct":721,"leadSponsor":723,"locationsCount":725},"100338062","phase-1-nivolumab-with-ruxolitinib-in-relapsed-or-refractory-classical-hodgkin-lymphoma-100338062","NCT03681561","Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma","Phase I\u002FII Study of Nivolumab in Combination With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma","Inclusion Criteria:\n\n* Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n* Age ≥ 18 years at the time of consent.\n* ECOG Performance Status of 0, 1 or 2.\n* Histologically confirmed diagnosis of classical Hodgkin lymphoma that is relapsed or refractory - historical biopsy at last relapse is acceptable. NOTE: a repeat biopsy is not required for Phase I if the historical biopsy was performed at the most recent relapse, without remission in between. A fresh biopsy is not required for Phase II.\n* Presence of radiographically measurable disease (defined as the presence one or more ≥ 1.5 cm lesions, as measured in the longest dimension by PET\u002FCT) within 4 weeks of study registration.\n* Prior therapy with check-point inhibitors (nivolumab, pembrolizumab, others) and subsequent progressive disease, stable disease, mixed response, or relapse\n* Failed at least one prior therapy\n* Prior cancer treatment must be completed at least 14 days prior to registration and the patient must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤Grade 1 or baseline. Radiation therapy must be completed at least 7 days prior to registration.\n* Absolute Neutrophil Count ≥ 1000\u002FμL\n* Platelets ≥ 75,000\u002FμL (or ≥50,000\u002Fmm3 if known BM involvement)\n* Calculated creatinine clearance ≥ 40 cc\u002Fmin using the Cockcroft-Gault formula\n* Bilirubin ≤ 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) ≤ 2.5 × ULN\n* Alanine aminotransferase (ALT) ≤ 2.5 × ULN\n* Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months\n* Males who are sexually active with partners of child-bearing potential must be willing to abstain from heterosexual activity or adhere to contraception from the time of written consent until 7 months after treatment discontinuation.\n* Patient must provide voluntary written informed consent prior to the performance of any research related tests or procedures.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).\n* Inability or unwillingness to swallow oral medication or any condition that precludes the administration and\u002For absorption of oral medications\n* A life-threatening illness, medical condition or organ system dysfunction, which in the investigator's opinion, could compromise the patient's safety, interfere with the metabolism of study drugs, or put the study outcomes at undue risk\n* Active central nervous system (CNS) involvement by lymphoma\n* Uncontrolled cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification\n* Concomitant therapy with immunosuppressive agents, including systemic corticosteroids (doses ≤ 10 mg\u002Fday prednisone or equivalent are permitted).\n* Has a history of autoimmune disease now or in past 3 years such as hepatitis, nephritis, hyperthyroidism, interstitial lung disease or colitis except vitiligo or alopecia, hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial.\n* Active Hepatitis B or C infection (defined as a positive Hepatitis B surface antigen (Ag) or detectable viral load by PCR). NOTES: Hepatitis B and C testing is required. Patients with positive Hepatitis B Ag may enroll if PCR is negative. Suppressive antiviral therapy should be considered for these patients as clinically indicated.\n* Currently active, clinically significant hepatic impairment Child-Pugh class B or C\n* Currently receiving a strong CYP3A4 Inhibitor (such as but not limited to boceprevir clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir\u002Fritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) or Fluconazole \\>200 mg\u002Fday. Washout period of 1 week is required.\n* History of stroke or intracranial hemorrhage within 6 months of study registration",{"count":713,"type":19},54,[91,56],"This is a Phase I\u002FII, multicenter, open-label, dose escalation\u002Fdose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).",[29],{"date":718,"type":36},"2026-06-12",{"date":720,"type":36},"2018-09-13",{"date":722,"type":19},"2027-07",{"name":724,"class":42},"Veronika Bachanova",6,{"id":727,"slug":728,"hasResults":12,"nctId":729,"briefTitle":730,"officialTitle":730,"acronym":4,"eligibilityCriteria":731,"healthyVolunteers":12,"sex":16,"minAge":732,"maxAge":733,"enrollmentInfo":734,"targetDuration":4,"studyType":20,"phases":736,"briefSummary":737,"conditions":738,"keywords":739,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":741,"lastUpdatePostDateStruct":742,"startDateStruct":743,"completionDateStruct":744,"leadSponsor":746,"locationsCount":43},"100610035","feasibility-of-high-intensity-interval-training-in-survivors-of-childhood-adolescent-and-young-adult-hodgkin-lymphoma-100610035","NCT07222345","Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma","Inclusion Criteria:\n\n* Participant has been diagnosed with Hodgkin lymphoma between the ages of 10 to 25 years.\n* Participant is between the ages of \\>10 and \\\u003C25 years old the time of enrollment.\n* Participant has completed treatment (end of chemotherapy for those not receiving radiation therapy or end of radiation therapy) for Hodgkin lymphoma within 24 months prior to enrollment and recovered from any acute treatment-related adverse events.\n* Participant has been medically cleared to participate in physical activity.\n* Participant verbalizes understanding of directions for use of the web-based platform on the study provided iPad and heart rate monitor.\n\nExclusion Criteria:\n\n* Participant has evidence of relapsed disease.\n* Participant has a diagnosis of acute heart failure.\n* Participant reports currently participating in HIIT training or \\>420 minutes per week of moderate to vigorous physical activity.\n* Female participant who is currently pregnant.","10 Years","25 Years",{"count":735,"type":19},20,[22],"This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated.\n\nPrimary Objective:\n\nTo determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment.\n\nFeasibility will be assessed by:\n\n* Participation Rate: Number of eligible survivors approached who enroll.\n* Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.",[29],[740],"Childhood Cancer Survivor","2026-06-08",{"date":696,"type":36},{"date":741,"type":36},{"date":745,"type":19},"2029-01",{"name":41,"class":42},{"id":748,"slug":749,"hasResults":12,"nctId":750,"briefTitle":751,"officialTitle":752,"acronym":753,"eligibilityCriteria":754,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":755,"targetDuration":4,"studyType":20,"phases":757,"briefSummary":758,"conditions":759,"keywords":765,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":741,"lastUpdatePostDateStruct":772,"startDateStruct":774,"completionDateStruct":776,"leadSponsor":778,"locationsCount":735},"100434327","phase-2-faecal-microbiota-transplantation-after-allogeneic-stem-cell-transplantation-100434327","NCT04935684","Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation","Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies","TMF-Allo","Inclusion Criteria:\n\n* Patient aged 18 or over\n* Men and women\n* Patients affiliated with a social-security organization\n* Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood)\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Status of tumor progression at the time of allo-HSCT\n* Inability to understand the protocol (linguistic barrier, cognitive difficulties)\n* Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma)\n* Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis)\n* Fecal incontinence\n* Participation in another clinical trial studying an allograft procedure including the type of graft, the type of immunosuppression, a preventive or a curative treatment of GvHD, or studying the effectiveness of a FMT in another indication.\n* Pregnant women\n* Patient under guardianship, curatorship or protection of justice",{"count":756,"type":19},150,[56],"The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).\n\nThe hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.",[760,761,762,29,763,764,272],"Acute Leukemia in Remission","Myelodysplastic Syndromes","Myeloproliferative Syndrome","Lymphoma, Non-Hodgkin","Myeloma",[766,767,768,769,770,771],"Allogeneic hematopoietic stem cell transplantation","Hematologic malignancies","Graft versus Host Disease","Intestinal microbiota","Intestinal dysbiosis","Fecal Microbiota Transplantation",{"date":773,"type":36},"2026-06-09",{"date":775,"type":36},"2022-12-20",{"date":777,"type":19},"2030-05",{"name":779,"class":42},"University Hospital, Clermont-Ferrand"]